BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164-176. [PMID: 8550036 DOI: 10.1002/hep.510230122] [Cited by in Crossref: 1019] [Cited by in F6Publishing: 798] [Article Influence: 40.8] [Reference Citation Analysis]
Number Citing Articles
1 Marrero J, Martinez FJ, Hyzy R. Advances in Critical Care Hepatology. Am J Respir Crit Care Med 2003;168:1421-6. [DOI: 10.1164/rccm.200303-361up] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
2 Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71:811-822. [PMID: 31302175 DOI: 10.1016/j.jhep.2019.07.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 55] [Article Influence: 38.5] [Reference Citation Analysis]
3 Appenrodt B, Zielinski J, Brensing KA, Heller J, Sauerbruch T, Schepke M. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis. Eur J Gastroenterol Hepatol 2009;21:1428-32. [PMID: 19794309 DOI: 10.1097/MEG.0b013e32832ec16a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Park J, Gwak G, Kim J, Oh H, Yi N, Suh K, Kim D, Lim C, Kim Y, Lee J. Renal Outcomes After Liver Transplantation in Fulminant Hepatitis A With Acute Kidney Injury: Comparison With Hepatorenal Syndrome. Transplantation Proceedings 2015;47:709-17. [DOI: 10.1016/j.transproceed.2014.10.057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-khac E, Duhamel C, Lebrec D, Poynard T, Moreau R. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007;46:1872-82. [DOI: 10.1002/hep.21920] [Cited by in Crossref: 168] [Cited by in F6Publishing: 150] [Article Influence: 12.0] [Reference Citation Analysis]
6 Krasko A, Deshpande K, Bonvino S. Liver failure, transplantation, and critical care. Critical Care Clinics 2003;19:155-83. [DOI: 10.1016/s0749-0704(02)00051-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, Fagiuoli S, Spadaccini A, Trotta E, Laffi G, Koch M, Riggio O, Boccia S, Felder M, Balzani S, Bruno S, Angeli P;  Italian Association of the Hospital Gastroenterologists (AIGO) investigators. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol. 2011;55:1241-1248. [PMID: 21703199 DOI: 10.1016/j.jhep.2011.03.012] [Cited by in Crossref: 58] [Cited by in F6Publishing: 44] [Article Influence: 5.8] [Reference Citation Analysis]
8 Artigas A, Wernerman J, Arroyo V, Vincent JL, Levy M. Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis. J Crit Care 2016;33:62-70. [PMID: 26831575 DOI: 10.1016/j.jcrc.2015.12.019] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
9 Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med. 1999;107:262-267. [PMID: 10492320 DOI: 10.1016/S0002-9343(99)00217-X] [Cited by in Crossref: 124] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
10 Perney P, Taourel P, Gallix B, Dauzat M, Joomaye Z, Djafari M, Fabro-peray P, Beaufort P, Petrissans B, Bruel JM, Blanc F. Changes in renal artery resistance after meal-induced splanchnic vasodilatation in cirrhotic patients. J Clin Ultrasound 2001;29:506-12. [DOI: 10.1002/jcu.10016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Ginès P, Fernández-Esparrach G, Arroyo V. Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. Baillieres Clin Gastroenterol 1997;11:365-85. [PMID: 9395753 DOI: 10.1016/s0950-3528(97)90045-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 Runyon BA. Ascites and Spontaneous Bacterial Peritonitis. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 1517-1541.e4. [DOI: 10.1016/b978-1-4160-6189-2.00091-3] [Cited by in Crossref: 12] [Article Influence: 1.1] [Reference Citation Analysis]
13 Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999;30:870-875. [PMID: 10498636 DOI: 10.1002/hep.510300430] [Cited by in Crossref: 137] [Cited by in F6Publishing: 103] [Article Influence: 6.2] [Reference Citation Analysis]
14 Gasteiger L, Eschertzhuber S, Tiefenthaler W. Perioperative management of liver surgery-review on pathophysiology of liver disease and liver failure. Eur Surg 2018;50:81-6. [PMID: 29875796 DOI: 10.1007/s10353-018-0522-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
15 Bloom RD, Bleicher M. Simultaneous Liver-Kidney Transplantation in the MELD Era. Advances in Chronic Kidney Disease 2009;16:268-77. [DOI: 10.1053/j.ackd.2009.05.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
16 Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Junuzovic D, Bijedic N, Sofic A, Bjelogrlic I, Mehmedovic A. Estimated Glomerular Filtration Rate (eGFR) Values as Predictor of Renal Insufficiency in Advanced Stages of Liver Diseases with Different Etiology. Med Arch 2014;68:159-62. [PMID: 25568524 DOI: 10.5455/medarh.2014.68.159-162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Eknoyan G, Epstein M. Hepatorenal syndrome: a historical appraisal of its origins and conceptual evolution. Kidney Int 2021;99:1321-30. [PMID: 33781792 DOI: 10.1016/j.kint.2021.02.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int 2018;12:122-34. [DOI: 10.1007/s12072-017-9815-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
19 Barakat M, Khalil M. Serum cystatin C in advanced liver cirrhosis and different stages of the hepatorenal syndrome. Arab Journal of Gastroenterology 2011;12:131-5. [DOI: 10.1016/j.ajg.2011.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
20 Wong F, Blendis L. THE PATHOPHYSIOLOGIC BASIS FOR THE TREATMENT OF CIRRHOTIC ASCITES. Clinics in Liver Disease 2001;5:819-32. [DOI: 10.1016/s1089-3261(05)70193-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Wadei HM, Gonwa TA. Hepatorenal syndrome in the intensive care unit. J Intensive Care Med. 2013;28:79-92. [PMID: 21859679 DOI: 10.1177/0885066611408692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, Peck-radosavljevic M; for the Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003;38:1043-50. [DOI: 10.1002/hep.1840380431] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
23 Lau T, Ahmad J. Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine. Hepat Med. 2013;5:1-10. [PMID: 24696621 DOI: 10.2147/hmer.s9049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
24 Hernández-gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, Miñana J, Guarner C, Villanueva C. Development of Ascites in Compensated Cirrhosis With Severe Portal Hypertension Treated With β-Blockers. American Journal of Gastroenterology 2012;107:418-27. [DOI: 10.1038/ajg.2011.456] [Cited by in Crossref: 87] [Cited by in F6Publishing: 63] [Article Influence: 9.7] [Reference Citation Analysis]
25 Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152-156. [PMID: 12542598 DOI: 10.1046/j.1440-1746.2003.02934.x] [Cited by in Crossref: 193] [Cited by in F6Publishing: 156] [Article Influence: 10.7] [Reference Citation Analysis]
26 Lenz K. Hepatorenal syndrome--is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? Hepatology 2005;42:263-5. [PMID: 16025501 DOI: 10.1002/hep.20832] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
27 Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology. 2002;122:1658-1676. [PMID: 12016430 DOI: 10.1053/gast.2002.33575] [Cited by in Crossref: 103] [Cited by in F6Publishing: 76] [Article Influence: 5.4] [Reference Citation Analysis]
28 Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. Journal of Hepatology 2003;38:24-31. [DOI: 10.1016/s0168-8278(02)00334-3] [Cited by in Crossref: 138] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
29 Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P. Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 2011;17:2273-82. [PMID: 21633593 DOI: 10.3748/wjg.v17.i18.2273] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
30 Pozzi M, Ratti L, Redaelli E, Guidi C, Mancia G. Cardiovascular abnormalities in special conditions of advanced cirrhosis. The circulatory adaptative changes to specific therapeutic procedures for the management of refractory ascites. Gastroenterol Hepatol 2006;29:263-72. [PMID: 16584698 DOI: 10.1157/13086820] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
31 Solé C, Solà E, Huelin P, Carol M, Moreira R, Cereijo U, Mas JM, Graupera I, Pose E, Napoleone L, dePrada G, Juanola A, Fabrellas N, Torres F, Morales-Ruiz M, Farrés J, Jiménez W, Ginès P. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver Int 2019;39:1246-55. [PMID: 30597709 DOI: 10.1111/liv.14037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
32 Schindler C, Ramadori G. Albumin substitution improves urinary sodium excretion and diuresis in patients with liver cirrhosis and refractory ascites. Journal of Hepatology 1999;31:1131. [DOI: 10.1016/s0168-8278(99)80329-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
33 Liu S, Wang X, Lu Y, Li T, Gong Z, Sheng T, Hu B, Peng Z, Sun X. The effects of intraoperative cryoprecipitate transfusion on acute renal failure following orthotropic liver transplantation. Hepatol Int 2013;7:901-9. [PMID: 26201928 DOI: 10.1007/s12072-013-9457-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
34 Di Campli C, Zocco M, Saulnier N, Grieco A, Rapaccini G, Addolorato G, Rumi C, Santoliquido A, Leone G, Gasbarrini G, Gasbarrini A. Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Digestive and Liver Disease 2007;39:1071-6. [DOI: 10.1016/j.dld.2007.08.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
35 Gordon FD. Ascites. Clin Liver Dis. 2012;16:285-299. [PMID: 22541699 DOI: 10.1016/j.cld.2012.03.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
36 Carl DE, Ghosh S, Cheng J, Gehr TW, Stravitz RT, Sanyal A. Post-paracentesis circulatory derangements are related to monocyte activation. Liver Int. 2014;34:1001-1007. [PMID: 24373155 DOI: 10.1111/liv.12450] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
37 Singh KK, Panda SK, Shalimar SK. Patients with Diabetes Mellitus are Prone to Develop Severe Hepatitis and Liver Failure due to Hepatitis Virus Infection. J Clin Exp Hepatol. 2013;3:275-280. [PMID: 25755514 DOI: 10.1016/j.jceh.2013.11.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
38 Papaluca T, Gow P. Terlipressin: Current and emerging indications in chronic liver disease: Current and emerging indications. Journal of Gastroenterology and Hepatology 2018;33:591-8. [DOI: 10.1111/jgh.14009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
39 Alukal JJ, John S, Thuluvath PJ. Hyponatremia in Cirrhosis: An Update. Am J Gastroenterol 2020;115:1775-85. [PMID: 33156095 DOI: 10.14309/ajg.0000000000000786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
40 Planas R, Bataller R, Rodés J. Hepatorenal Syndrome. Curr Treat Options Gastroenterol 2000;3:445-50. [PMID: 11096604 DOI: 10.1007/s11938-000-0032-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Novellas S, Denys A, Bize P, Brunner P, Motamedi JP, Gugenheim J, Caroli FX, Chevallier P. Palliative portal vein stent placement in malignant and symptomatic extrinsic portal vein stenosis or occlusion. Cardiovasc Intervent Radiol. 2009;32:462-470. [PMID: 18956224 DOI: 10.1007/s00270-008-9455-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
42 Huggins JT, Doelken P, Walters C, Rockey DC. Point-of-Care Echocardiography Improves Assessment of Volume Status in Cirrhosis and Hepatorenal Syndrome. Am J Med Sci. 2016;351:550-553. [PMID: 27140719 DOI: 10.1016/j.amjms.2016.02.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
43 Singhal S, Baikati KK, Jabbour II, Anand S. Management of refractory ascites. Am J Ther. 2012;19:121-132. [PMID: 21192246 DOI: 10.1097/mjt.0b013e3181ff7a8b] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
44 Lata J. Hepatorenal syndrome. World J Gastroenterol 2012;18:4978-84. [PMID: 23049205 DOI: 10.3748/wjg.v18.i36.4978] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
45 Guevara M, Fernández-Esparrach G, Alessandria C, Torre A, Terra C, Montañà X, Piera C, Alvarez ML, Jiménez W, Ginès P, Arroyo V. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 2004;40:646-51. [PMID: 15349903 DOI: 10.1002/hep.20373] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
46 Romero-gómez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 2004;39:939-43. [DOI: 10.1002/hep.20152] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
47 Jaurigue MM, Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol. 2014;20:2143-2158. [PMID: 24605013 DOI: 10.3748/wjg.v20.i9.2143] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
48 Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123:1839-1847. [PMID: 12454841 DOI: 10.1053/gast.2002.37073] [Cited by in Crossref: 380] [Cited by in F6Publishing: 277] [Article Influence: 20.0] [Reference Citation Analysis]
49 Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8. [PMID: 17389705 DOI: 10.1136/gut.2006.107789] [Cited by in Crossref: 115] [Cited by in F6Publishing: 247] [Article Influence: 8.2] [Reference Citation Analysis]
50 Leithead JA, Ferguson JW, Bates CM, Davidson JS, Simpson KJ, Hayes PC. Chronic Kidney Disease After Liver Transplantation for Acute Liver Failure Is Not Associated With Perioperative Renal Dysfunction: Acute Liver Failure: Posttransplant Renal Function. American Journal of Transplantation 2011;11:1905-15. [DOI: 10.1111/j.1600-6143.2011.03649.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
51 Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation. 2011;91:1141-1147. [PMID: 21544034 DOI: 10.1097/tp.0b013e31821690bf] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
52 Smalberg JH, Leebeek FWG. Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin Liver Dis 2009;13:33-42. [PMID: 19150307 DOI: 10.1016/j.cld.2008.09.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
53 Umbro I, Tinti F, Fiacco F, Zavatto A, Di Natale V, Ginanni Corradini S, Rossi M, Poli L, Berloco PB, Mitterhofer AP. From listing to transplant: nephrologic monitoring in cirrhotic patients awaiting liver transplantation. Transplant Proc 2013;45:2672-5. [PMID: 24034021 DOI: 10.1016/j.transproceed.2013.07.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Firriolo FJ. Dental Management of Patients with End-Stage Liver Disease. Dental Clinics of North America 2006;50:563-90. [DOI: 10.1016/j.cden.2006.06.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
55 Rajakumar A, Appuswamy E, Kaliamoorthy I, Rela M. Renal Dysfunction in Cirrhosis: Critical Care Management. Indian J Crit Care Med 2021;25:207-14. [PMID: 33707901 DOI: 10.5005/jp-journals-10071-23721] [Reference Citation Analysis]
56 Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, Meregaglia D, Nicolini A. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56:869-875. [PMID: 17135305 DOI: 10.1136/gut.2006.102467] [Cited by in Crossref: 144] [Cited by in F6Publishing: 111] [Article Influence: 9.6] [Reference Citation Analysis]
57 Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011;55:315-21. [PMID: 21167235 DOI: 10.1016/j.jhep.2010.11.020] [Cited by in Crossref: 137] [Cited by in F6Publishing: 113] [Article Influence: 12.5] [Reference Citation Analysis]
58 Zhang J, Rössle M, Zhou X, Deng J, Liu L, Qi X. Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. Current Medical Research and Opinion 2019;35:859-68. [DOI: 10.1080/03007995.2018.1552575] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
59 Rice JB, White AG, Galebach P, Korenblat KM, Wagh A, Lovelace B, Wan GJ, Jamil K. The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States. Current Medical Research and Opinion 2017;33:1473-80. [DOI: 10.1080/03007995.2017.1331211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
60 Wong F, Blendis L. HEPATORENAL FAILURE. Clinics in Liver Disease 2000;4:169-89. [DOI: 10.1016/s1089-3261(05)70102-1] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
61 Kim WR. Models predicting the natural history of cirrhosis and need for liver transplantation: . Current Opinion in Organ Transplantation 2001;6:107-13. [DOI: 10.1097/00075200-200106000-00002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
62 Giefer MJ, Murray KF, Colletti RB. Pathophysiology, Diagnosis, and Management of Pediatric Ascites. Journal of Pediatric Gastroenterology & Nutrition 2011;52:503-13. [DOI: 10.1097/mpg.0b013e318213f9f6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
63 Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499-505. [PMID: 17560680 DOI: 10.1016/j.jhep.2007.04.010] [Cited by in Crossref: 197] [Cited by in F6Publishing: 154] [Article Influence: 14.1] [Reference Citation Analysis]
64 Carrion AF, Aye L, Martin P. Patient selection for liver transplantation. Expert Rev Gastroenterol Hepatol. 2013;7:571-579. [PMID: 23985006 DOI: 10.1586/17474124.2013.824701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
65 Wongcharatrawee S, Garcia-Tsao G. Clinical management of ascites and its complications. Clin Liver Dis. 2001;5:833-850. [PMID: 11565143 DOI: 10.1016/S1089-3261(05)70194-X] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
66 Eckardt K, Frei U. Reversibility of hepatorenal syndrome in an anuric patient with Child C cirrhosis requiring haemodialysis for 7 weeks. Nephrology Dialysis Transplantation 2000;15:1063-5. [DOI: 10.1093/ndt/15.7.1063] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
67 Uemura M, Tsujii T, Kikuchi E, Fukui H, Tsukamoto N, Matsumura M, Fujimoto M, Koizumi M, Takaya A, Kojima H. Increased plasma levels of substance P and disturbed water excretion in patients with liver cirrhosis. Scand J Gastroenterol. 1998;33:860-866. [PMID: 9754735 DOI: 10.1080/00365529850171530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
68 Oberkofler CE, Dutkowski P, Stocker R, Schuepbach RA, Stover JF, Clavien PA, Béchir M. Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Crit Care. 2010;14:R117. [PMID: 20550662 DOI: 10.1186/cc9068] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
69 Pillai AK, Andring B, Patel A, Trimmer C, Kalva SP. Portal hypertension: a review of portosystemic collateral pathways and endovascular interventions. Clin Radiol. 2015;70:1047-1059. [PMID: 26188844 DOI: 10.1016/j.crad.2015.06.077] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
70 Nickovic VP, Miric D, Kisic B, Kocic H, Stojanovic M, Buttice S, Kocic G. Oxidative stress, NOx/l-arginine ratio and glutathione/glutathione S-transferase ratio as predictors of 'sterile inflammation' in patients with alcoholic cirrhosis and hepatorenal syndrome type II. Ren Fail 2018;40:340-9. [PMID: 29658815 DOI: 10.1080/0886022X.2018.1459699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
71 Stanley, Forrest, Dabos, Gilchrist, Hayes. Comparison between theophylline and spironolactone in the management of cirrhotic ascites: a randomized controlled study: THEOPHYLLINE VERSUS SPIRONOLACTONE FOR ASCITES. Alimentary Pharmacology & Therapeutics 1998;12:389-93. [DOI: 10.1046/j.1365-2036.1998.00318.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
72 Bauer M, Winning J, Kortgen A. Liver failure. Current Opinion in Anaesthesiology 2005;18:111-6. [DOI: 10.1097/01.aco.0000162827.74270.32] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
73 Planas R, Montoliu S, Ballesté B, Rivera M, Miquel M, Masnou H, Galeras JA, Giménez MD, Santos J, Cirera I. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385-1394. [PMID: 17081806 DOI: 10.1016/j.cgh.2006.08.007] [Cited by in Crossref: 236] [Cited by in F6Publishing: 173] [Article Influence: 16.9] [Reference Citation Analysis]
74 Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288-295. [PMID: 10896924 DOI: 10.1136/gut.47.2.288] [Cited by in Crossref: 322] [Cited by in F6Publishing: 211] [Article Influence: 15.3] [Reference Citation Analysis]
75 Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: Evidence for present indications. J Gastroenterol Hepatol. 2011;26 Suppl 1:109-114. [PMID: 21199521 DOI: 10.1111/j.1440-1746.2010.06583.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
76 Ochs A. Transjugular intrahepatic portosystemic shunt. Dig Dis. 2005;23:56-64. [PMID: 15920326 DOI: 10.1159/000084726] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
77 Sanchez LO, Francoz C. Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis. United European Gastroenterol J 2021;9:220-8. [PMID: 33337286 DOI: 10.1177/2050640620980713] [Reference Citation Analysis]
78 Cárdenas A, Arroyo V. Management of ascites and hepatic hydrothorax. Best Pract Res Clin Gastroenterol. 2007;21:55-75. [PMID: 17223497 DOI: 10.1016/j.bpg.2006.07.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
79 Rivolta R, Maggi A, Cazzaniga M, Castagnone D, Panzeri A, Solenghi D, Lorenzano E, di Palo FQ, Salerno F. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology. 1998;28:1235-1240. [PMID: 9794906 DOI: 10.1002/hep.510280510] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
80 Catalina-Rodríguez MV, Bañares-Cañizares R. [Artificial liver support systems: update on albumin dialysis (MARS)]. Gastroenterol Hepatol 2005;28:453-60. [PMID: 16185581 DOI: 10.1157/13078996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
81 Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010;53:1135-45. [PMID: 20850887 DOI: 10.1016/j.jhep.2010.08.001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
82 Gentilini P, Bernardi M, Bolondi L, Craxi A, Gasbarrinie G, Ideo G, Laffi G, La Villa G, Salerno F, Ventura E, Pulazzini A, Segantini L, Romanelli RG. The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards. Dig Liver Dis 2004;36:539-46. [PMID: 15334775 DOI: 10.1016/j.dld.2004.03.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
83 Nguyen-khac E, Thevenot T, Capron D, Dharancy S, Paupart T, Thabut D, Tiry C. Are ascitic electrolytes usable in cirrhotic patients? Correlation of sodium, potassium, chloride, urea, and creatinine concentrations in ascitic fluid and blood. European Journal of Internal Medicine 2008;19:613-8. [DOI: 10.1016/j.ejim.2007.07.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
84 Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR;  TRIBE-AKI Consortium. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2013;57:753-762. [PMID: 22454364 DOI: 10.1002/hep.25735] [Cited by in Crossref: 205] [Cited by in F6Publishing: 172] [Article Influence: 22.8] [Reference Citation Analysis]
85 Schrier RW. Use of diuretics in heart failure and cirrhosis. Semin Nephrol 2011;31:503-12. [PMID: 22099507 DOI: 10.1016/j.semnephrol.2011.09.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
86 Ferrarese A, Vitale A, Sgarabotto D, Russo FP, Germani G, Gambato M, Cattelan AM, Angeli P, Cillo U, Burra P, Senzolo M. Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. Liver Transpl. 2019;25:1187-1197. [PMID: 31021050 DOI: 10.1002/lt.25479] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
87 Nasr G, Hassan A, Ahmed S, Serwah A. Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res 2010;1:136-44. [PMID: 21187868 DOI: 10.4103/0975-3583.70914] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
88 Pham PT, Pham PT, Wilkinson AH. Renal Failure in Adult Liver Transplant Recipients. Transplantation of the Liver. Elsevier; 2005. pp. 891-914. [DOI: 10.1016/b978-0-7216-0118-2.50065-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Angeli P, Sanyal A, Moller S, Alessandria C, Gadano A, Kim R, Sarin SK, Bernardi M; International Club of Ascites. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int 2013;33:16-23. [PMID: 22507181 DOI: 10.1111/j.1478-3231.2012.02807.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
90 Doria C, Doyle H, Mandalà L, Marino I, Caruana G, Gruttadauria S, Lauro A, Magnone M, Foglieni CS, Lamonaca V, Scott V. Changes in Serum Electrolytes during Treatment of Patients in Liver Failure with Molecular Adsorbent Recirculating System. The International Journal of Artificial Organs 2018;26:918-23. [DOI: 10.1177/039139880302601008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
91 Londoño MC, Cárdenas A, Guevara M, Quintó L, de Las Heras D, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Ginès P. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283-1290. [PMID: 17452425 DOI: 10.1136/gut.2006.102764] [Cited by in Crossref: 136] [Cited by in F6Publishing: 113] [Article Influence: 9.7] [Reference Citation Analysis]
92 Moreau R, Lebrec D. Transduction of antinatriuretic signals in renal proximal tubular cells in cirrhosis: introduction to novel approaches to the treatment of sodium retention. J Hepatol 1998;28:1064-9. [PMID: 9672185 DOI: 10.1016/s0168-8278(98)80358-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
93 Strauss E, Caly WR. [Spontaneous bacterial peritonitis]. Rev Soc Bras Med Trop 2003;36:711-7. [PMID: 15049112 DOI: 10.1590/s0037-86822003000600012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
94 Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61:660-667. [PMID: 25284616 DOI: 10.1002/hep.27546] [Cited by in Crossref: 224] [Cited by in F6Publishing: 166] [Article Influence: 37.3] [Reference Citation Analysis]
95 Vila MC, Solà R, Molina L, Andreu M, Coll S, Gana J, Marquez J, Palá J, Bory F, Pons S. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol. 1998;28:639-645. [PMID: 9566833 DOI: 10.1016/s0168-8278(98)80288-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
96 Bittencourt PL, Farias AQ, Terra C. Renal failure in cirrhosis: Emerging concepts. World J Hepatol. 2015;7:2336-2343. [PMID: 26413223 DOI: 10.4254/wjh.v7.i21.2336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
97 Al-khafaji A, Nadim MK, Kellum JA. Hepatorenal Disorders. Chest 2015;148:550-8. [DOI: 10.1378/chest.14-1925] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
98 Vaz K, Little R, Majeed A, Kemp W, Roberts SK. Determinants of Short- and Long-Term Outcomes of an Australian Cohort of Patients Admitted with Alcoholic Hepatitis. Dig Dis Sci 2021. [PMID: 34231100 DOI: 10.1007/s10620-021-07140-w] [Reference Citation Analysis]
99 Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52:605-613. [PMID: 20185192 DOI: 10.1016/j.jhep.2009.11.025] [Cited by in Crossref: 155] [Cited by in F6Publishing: 121] [Article Influence: 14.1] [Reference Citation Analysis]
100 Mohamed MMG, Rauf A, Adam A, Kheiri B, Lacasse A, El-Halawany H. Terlipressin effect on hepatorenal syndrome: Updated meta-analysis of randomized controlled trials. JGH Open 2021;5:896-901. [PMID: 34386597 DOI: 10.1002/jgh3.12600] [Reference Citation Analysis]
101 Sorrentino P, Castaldo G, Tarantino L, Bracigliano A, Perrella A, Perrella O, Fiorentino F, Vecchione R, D' Angelo S. Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis. J Gastroenterol Hepatol 2012;27:813-22. [PMID: 22142548 DOI: 10.1111/j.1440-1746.2011.07043.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
102 Sourianarayanane A, Raina R, Garg G, McCullough AJ, O'Shea RS. Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients. Int Urol Nephrol. 2014;46:793-800. [PMID: 23934619 DOI: 10.1007/s11255-013-0527-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
103 Kadam N, Acharya S, Shukla S, Gupta K. Ascitic Fluid High Sensitive C-Reactive Protein (hs-CRP). A Prognostic Marker in Cirrhosis with Spontaneous Bacterial Peritonitis. J Clin Diagn Res. 2016;10:OC20-OC24. [PMID: 27190862 DOI: 10.7860/jcdr/2016/17931.7610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
104 Fernández J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM, Ginès P, Arroyo V. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology. 2006;44:1288-1295. [PMID: 17058239 DOI: 10.1002/hep.21352] [Cited by in Crossref: 196] [Cited by in F6Publishing: 143] [Article Influence: 13.1] [Reference Citation Analysis]
105 Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923-930. [PMID: 11910344 DOI: 10.1053/gast.2002.32364] [Cited by in Crossref: 308] [Cited by in F6Publishing: 225] [Article Influence: 16.2] [Reference Citation Analysis]
106 Solé C, Pose E, Solà E, Ginès P. Hepatorenal syndrome in the era of acute kidney injury.Liver Int. 2018;38:1891-1901. [PMID: 29845739 DOI: 10.1111/liv.13893] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
107 Zapater P, Francés R, González-Navajas JM, de la Hoz MA, Moreu R, Pascual S, Monfort D, Montoliu S, Vila C, Escudero A. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008;48:1924-1931. [PMID: 19003911 DOI: 10.1002/hep.22564] [Cited by in Crossref: 115] [Cited by in F6Publishing: 106] [Article Influence: 9.6] [Reference Citation Analysis]
108 Lee JP, Kwon HY, Park JI, Yi NJ, Suh KS, Lee HW, Kim M, Oh YK, Lim CS, Kim YS. Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation. Liver Transpl. 2012;18:1237-1244. [PMID: 22714872 DOI: 10.1002/lt.23493] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
109 Bucsics T, Mandorfer M, Schwabl P, Bota S, Sieghart W, Ferlitsch A, Trauner M, Peck-Radosavljevic M, Reiberger T. Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. J Gastroenterol Hepatol. 2015;30:1657-1665. [PMID: 25967931 DOI: 10.1111/jgh.13002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
110 Garioud A, Cadranel J, Pauwels A, Nousbaum J, Thévenot T, Dao T, Louvet A, Sogni P, Talbodec N, Antonini TM, Bureau C, Thabut D, Elkrief L, Jouannaud V, Macaigne G, Bernard-chabert B, Lison H, Alric L, Carbonell N, Labadie H, Amiot X, Abergel A, Hanslik B, Leroy V, De Lédinghen V, Denis J. Albumin Use in Patients With Cirrhosis in France: Results of the “ALBU-LIVE” Survey: A Case for Better EASL Guidelines Diffusion and/or Revision. Journal of Clinical Gastroenterology 2017;51:831-8. [DOI: 10.1097/mcg.0000000000000735] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
111 Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol. 2000;33:43-48. [PMID: 10905585 DOI: 10.1016/s0168-8278(00)80158-0] [Cited by in Crossref: 276] [Cited by in F6Publishing: 39] [Article Influence: 13.1] [Reference Citation Analysis]
112 Durand F, Graupera I, Ginès P, Olson JC, Nadim MK. Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. Am J Kidney Dis 2016;67:318-28. [PMID: 26500178 DOI: 10.1053/j.ajkd.2015.09.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
113 Consigny Y. Prise en charge d’un hydrothorax. Gastroentérologie Clinique et Biologique 2004;28:146-55. [DOI: 10.1016/s0399-8320(04)95250-5] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
114 Mukerji AN, Patel V, Jain A. Improving survival in decompensated cirrhosis. Int J Hepatol. 2012;2012:318627. [PMID: 22811919 DOI: 10.1155/2012/318627] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
115 Garcia-tsao G. Ascites. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 283-95. [DOI: 10.1016/b978-1-4377-0881-3.00018-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
116 Albillos A, Bañares R, González M, Catalina M, Molinero L. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. Journal of Hepatology 2005;43:990-6. [DOI: 10.1016/j.jhep.2005.06.005] [Cited by in Crossref: 114] [Cited by in F6Publishing: 79] [Article Influence: 7.1] [Reference Citation Analysis]
117 Cerqueira de Carvalho G, de Andrade Regis C, Rosário Kalil J, Aparício Cerqueira L, Silva Barbosa D, Pamponet Motta M, da Silva Nery M, Alice Pires Soares M, Celestino Zollinger C, Lisboa Bittencourt P. Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality. Annals of Hepatology 2012;11:90-5. [DOI: 10.1016/s1665-2681(19)31491-7] [Cited by in Crossref: 28] [Article Influence: 3.1] [Reference Citation Analysis]
118 Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, Katakura T, Atsukawa M, Taki Y, Kimura Y, Nakatsuka K, Sakamoto C. Transjugular intrahepatic portosystemic shunt vs paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol. 2011;46:78-85. [PMID: 20632194 DOI: 10.1007/s00535-010-0282-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 8.2] [Reference Citation Analysis]
119 Park HS, Desser TS, Jeffrey RB, Kamaya A. Doppler Ultrasound in Liver Cirrhosis: Correlation of Hepatic Artery and Portal Vein Measurements With Model for End-Stage Liver Disease Score: Doppler Ultrasound in Liver Cirrhosis. J Ultrasound Med 2017;36:725-30. [DOI: 10.7863/ultra.16.03107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
120 Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, Graupera I, Brujats A, Vilades D, Colomo A, Poca M, Torras X, Guarner C, Concepción M, Aracil C, Torres F, Villanueva C. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol 2020;73:829-41. [PMID: 32298768 DOI: 10.1016/j.jhep.2020.03.048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
121 Alsebaey A, Rewisha E, Waked I. Paracentesis-induced circulatory dysfunction: are there albumin alternatives? Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00047-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Annals of Hepatology 2002;1:72-9. [DOI: 10.1016/s1665-2681(19)32178-7] [Cited by in Crossref: 31] [Article Influence: 1.6] [Reference Citation Analysis]
123 Arroyo V, Moreau R, Jalan R, Gines P. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis. J Hepatol. 2015;S131-S143. [PMID: 25920082 DOI: 10.1016/j.jhep.2014.11.045] [Cited by in Crossref: 244] [Cited by in F6Publishing: 184] [Article Influence: 48.8] [Reference Citation Analysis]
124 La Villa G, Gentilini P. Hemodynamic alterations in liver cirrhosis. Mol Aspects Med. 2008;29:112-118. [PMID: 18177931 DOI: 10.1016/j.mam.2007.09.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
125 Leithead JA, Hayes PC, Ferguson JW. Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Aliment Pharmacol Ther. 2014;39:699-711. [PMID: 24528130 DOI: 10.1111/apt.12653] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
126 Cárdenas A, Arroyo V. Refractory ascites. Dig Dis. 2005;23:30-38. [PMID: 15920323 DOI: 10.1159/000084723] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
127 Chirapongsathorn S, Valentin N, Alahdab F, Krittanawong C, Erwin PJ, Murad MH, Kamath PS. Nonselective β-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016;14:1096-1104.e9. [PMID: 26829026 DOI: 10.1016/j.cgh.2016.01.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 8.4] [Reference Citation Analysis]
128 Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol. 1999;30:639-645. [PMID: 10207805 DOI: 10.1016/s0168-8278(99)80194-9] [Cited by in Crossref: 141] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
129 Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol 2011;17:1237-48. [PMID: 21455322 DOI: 10.3748/wjg.v17.i10.1237] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
130 Bataller R, Ginès P, Arroyo V, Rodés J. Hepatorenal syndrome. Clin Liver Dis. 2000;4:487-507. [PMID: 11232202 DOI: 10.1016/s1089-3261(05)70120-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
131 Shaw E, Castellote J, Santín M, Xiol X, Euba G, Gudiol C, Lopez C, Ariza X, Gudiol F. Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a case-control study. Eur J Clin Microbiol Infect Dis 2006;25:291-8. [DOI: 10.1007/s10096-006-0136-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
132 Burroughs AK. Is the use of albumin of value in cirrhosis? The case not so in favour, or is there an alternative? Dig Liver Dis 2003;35:664-7. [PMID: 14563191 DOI: 10.1016/s1590-8658(03)00386-4] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
133 Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, Harry D, Moore K. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999;353:294-295. [PMID: 9929029 DOI: 10.1016/s0140-6736(05)74933-3] [Cited by in Crossref: 113] [Cited by in F6Publishing: 14] [Article Influence: 5.1] [Reference Citation Analysis]
134 Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, Pichler L, Wichlas M, Kreil A, Schmid M, Ferlitsch A, Lipinski E, Brunner H, Lammer J, Ferenci P, Gangl A, Peck-Radosavljevic M. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52:879-885. [PMID: 12740346 DOI: 10.1136/gut.52.6.879] [Cited by in Crossref: 188] [Cited by in F6Publishing: 169] [Article Influence: 10.4] [Reference Citation Analysis]
135 Tong GD, Zhou DQ, He JS, Zhang L, Chen ZF, Xiao CL, Peng LS. Clinical research on navel application of Shehuang Paste combined with Chinese herbal colon dialysis in treatment of refractory cirrhotic ascites complicated with azotemia. World J Gastroenterol 2006;12:7798-804. [PMID: 17203523 DOI: 10.3748/wjg.v12.i48.7798] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
136 Sato K, Kawagishi N, Fujimori K, Ohuchi N, Satomi S. Renal function status in liver transplant patients in the first month post-transplant is associated with progressive chronic kidney disease. Hepatol Res. 2015;45:220-227. [PMID: 24698087 DOI: 10.1111/hepr.12339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
137 Lim JK, Groszmann RJ. Vasoconstrictor Therapy for the Hepatorenal Syndrome. Gastroenterology 2008;134:1608-11. [DOI: 10.1053/j.gastro.2008.03.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
138 Legaz I, Bolarin JM, Campillo JA, Moya RM, Luna A, Osuna E, Minguela A, Sanchez-Bueno F, Alvarez MR, Muro M. Pretransplant ascites and encephalopathy and their influence on survival and liver graft rejection in alcoholic cirrhosis disease. Arch Med Sci 2021;17:682-93. [PMID: 34025838 DOI: 10.5114/aoms.2018.80651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
139 Kayali Z, Herring J, Baron P, Franco E, Ojogho O, Smith J, Watkins G, Smith D, Lamin V, Hoang T, Sharma R, Mathahs M, Sowers L, Brown KE, Schmidt WN. Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. J Gastroenterol Hepatol 2009;24:1030-7. [PMID: 19226382 DOI: 10.1111/j.1440-1746.2008.05757.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
140 Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ. 2020;370:m2687. [PMID: 32928750 DOI: 10.1136/bmj.m2687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
141 Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis 2015;6:124-37. [PMID: 25954497 DOI: 10.1177/2040622315580069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
142 Moreno C, Langlet P, Hittelet A, Lasser L, Degré D, Evrard S, Colle I, Lemmers A, Devière J, Le Moine O. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010;53:1117-1122. [PMID: 20801542 DOI: 10.1016/j.jhep.2010.05.030] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
143 Juanola A, Solé C, Toapanta D, Ginès P, Solà E. Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. Clin Liver Dis 2021;25:441-60. [PMID: 33838860 DOI: 10.1016/j.cld.2021.01.011] [Reference Citation Analysis]
144 Yousef N, Habes D, Ackermann O, Durand P, Bernard O, Jacquemin E. Hepatorenal syndrome: diagnosis and effect of terlipressin therapy in 4 pediatric patients. J Pediatr Gastroenterol Nutr 2010;51:100-2. [PMID: 20543721 DOI: 10.1097/MPG.0b013e3181d60e73] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
145 Oberkofler CE, Stocker R, Raptis DA, Stover JF, Schuepbach RA, Müllhaupt B, Dutkowski P, Clavien P, Béchir M. Same quality - higher price? The paradox of allocation: the first national single center analysis after the implementation of the new Swiss transplantation law: the ICU view: Paradox of allocation in Switzerland. Clinical Transplantation 2011;25:921-8. [DOI: 10.1111/j.1399-0012.2010.01364.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
146 Cárdenas A, Ginès P. Therapy insight: Management of hepatorenal syndrome. Nat Clin Pract Gastroenterol Hepatol. 2006;3:338-348. [PMID: 16741553 DOI: 10.1038/ncpgasthep0517] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
147 Arroyo V, Jiménez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. Journal of Hepatology 2000;32:157-70. [DOI: 10.1016/s0168-8278(00)80423-7] [Cited by in Crossref: 125] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
148 Poonja Z, Brisebois A, van Zanten SV, Tandon P, Meeberg G, Karvellas CJ. Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol. 2014;12:692-698. [PMID: 23978345 DOI: 10.1016/j.cgh.2013.08.027] [Cited by in Crossref: 127] [Cited by in F6Publishing: 89] [Article Influence: 15.9] [Reference Citation Analysis]
149 Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R, Lebrec D. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794-799. [PMID: 21354230 DOI: 10.1016/j.jhep.2011.01.034] [Cited by in Crossref: 128] [Cited by in F6Publishing: 95] [Article Influence: 12.8] [Reference Citation Analysis]
150 Makhlouf NA, Morsy KH. Renal failure after upper-gastrointestinal bleeding among cirrhotic patients in Upper Egypt. Arab J Gastroenterol 2012;13:139-44. [PMID: 23122456 DOI: 10.1016/j.ajg.2012.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
151 Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol. 1998;29:565-570. [PMID: 9824265 DOI: 10.1016/s0168-8278(98)80151-7] [Cited by in Crossref: 147] [Cited by in F6Publishing: 25] [Article Influence: 6.7] [Reference Citation Analysis]
152 Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002;36:941-8. [DOI: 10.1053/jhep.2002.35819] [Cited by in Crossref: 369] [Cited by in F6Publishing: 268] [Article Influence: 20.5] [Reference Citation Analysis]
153 Rössle M, Grandt D. TIPS: an update. Best Pract Res Clin Gastroenterol. 2004;18:99-123. [PMID: 15123087 DOI: 10.1016/j.bpg.2003.08.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
154 Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. Journal of Hepatology 2003;38:69-89. [DOI: 10.1016/s0168-8278(03)00007-2] [Cited by in Crossref: 188] [Cited by in F6Publishing: 44] [Article Influence: 10.4] [Reference Citation Analysis]
155 Yang X, Lu Q, Tang T, Liao R, Yang Z. Prediction of the prognosis after liver transplantation in severe hepatitis B–induced liver failure and clinical decision for liver transplantation. Journal of Surgical Research 2013;183:846-51. [DOI: 10.1016/j.jss.2013.01.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
156 Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-8. [PMID: 17235705 DOI: 10.1007/s10620-006-9312-0] [Cited by in Crossref: 118] [Cited by in F6Publishing: 86] [Article Influence: 8.4] [Reference Citation Analysis]
157 Kalambokis G, Economou M, Kosta P, Papadimitriou K, Tsianos EV. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites. J Clin Gastroenterol 2006;40:342-6. [PMID: 16633107 DOI: 10.1097/01.mcg.0000210101.74618.61] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
158 Siddiqui MS, Stravitz RT. Intensive care unit management of patients with liver failure. Clin Liver Dis. 2014;18:957-978. [PMID: 25438294 DOI: 10.1016/j.cld.2014.07.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
159 Dourakis SP, Geladari E, Geladari C, Vallianou N. Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased? Curr Cardiol Rev 2021;17:78-84. [PMID: 31072296 DOI: 10.2174/1573403X15666190509084519] [Reference Citation Analysis]
160 Klinzing S, Brandi G, Stehberger PA, Raptis DA, Béchir M. The combination of MELD score and ICG liver testing predicts length of stay in the ICU and hospital mortality in liver transplant recipients. BMC Anesthesiol. 2014;14:103. [PMID: 25844060 DOI: 10.1186/1471-2253-14-103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
161 Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.Nat Rev Nephrol. 2020;16:137-155. [PMID: 31723234 DOI: 10.1038/s41581-019-0218-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
162 Hanafy AS, Hassaneen AM. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. Eur J Gastroenterol Hepatol. 2016;28:1455-1461. [PMID: 27622998 DOI: 10.1097/meg.0000000000000743] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
163 Tandon P, James MT, Abraldes JG, Karvellas CJ, Ye F, Pannu N. Relevance of New Definitions to Incidence and Prognosis of Acute Kidney Injury in Hospitalized Patients with Cirrhosis: A Retrospective Population-Based Cohort Study. PLoS One 2016;11:e0160394. [PMID: 27504876 DOI: 10.1371/journal.pone.0160394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
164 Singh V, Singh A, Singh B, Vijayvergiya R, Sharma N, Ghai A, Bhalla A. Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. Am J Gastroenterol. 2013;108:560-567. [PMID: 23419385 DOI: 10.1038/ajg.2013.9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
165 Peck-Radosavljevic M, Angermayr B, Datz C, Ferlitsch A, Ferlitsch M, Fuhrmann V, Häfner M, Kramer L, Maieron A, Payer B. Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr. 2013;125:200-219. [PMID: 23579878 DOI: 10.1007/s00508-013-0337-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
166 Garcia–tsao G. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001;120:726-48. [DOI: 10.1053/gast.2001.22580] [Cited by in Crossref: 292] [Cited by in F6Publishing: 228] [Article Influence: 14.6] [Reference Citation Analysis]
167 Kalambokis G, Tsianos EV. Refractory ascites: can it be defined only by the response to furosemide and spironolactone? Liver International 2010;30:1394-1394. [DOI: 10.1111/j.1478-3231.2010.02328.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
168 Al-Khafaji A, Huang DT. Critical care management of patients with end-stage liver disease. Crit Care Med 2011;39:1157-66. [PMID: 21336121 DOI: 10.1097/CCM.0b013e318211fdc4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
169 Israelsen M, Dahl EK, Madsen BS, Wiese S, Bendtsen F, Møller S, Fialla AD, Jensen BL, Krag A. Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. Am J Physiol Gastrointest Liver Physiol 2020;318:G313-21. [PMID: 31841026 DOI: 10.1152/ajpgi.00328.2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Lee WJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis. Korean J Hepatol 2011;17:292-8. [PMID: 22310793 DOI: 10.3350/kjhep.2011.17.4.292] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
171 Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-llahí M, Baccaro ME, Navasa M, Bru C, Arroyo V, Rodés J, Ginès P. Renal Failure in Patients With Cirrhosis and Sepsis Unrelated to Spontaneous Bacterial Peritonitis: Value of MELD Score. Gastroenterology 2005;129:1944-53. [DOI: 10.1053/j.gastro.2005.09.024] [Cited by in Crossref: 174] [Cited by in F6Publishing: 146] [Article Influence: 10.9] [Reference Citation Analysis]
172 Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64. [PMID: 15239086 DOI: 10.1002/hep.20262] [Cited by in Crossref: 259] [Cited by in F6Publishing: 178] [Article Influence: 15.2] [Reference Citation Analysis]
173 Martín–llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, Solá E, Pereira G, Marinelli M, Pavesi M, Fernández J, Rodés J, Arroyo V, Ginès P. Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. Gastroenterology 2011;140:488-496.e4. [DOI: 10.1053/j.gastro.2010.07.043] [Cited by in Crossref: 217] [Cited by in F6Publishing: 170] [Article Influence: 21.7] [Reference Citation Analysis]
174 Tan HK, James PD, Sniderman KW, Wong F. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. J Gastroenterol Hepatol. 2015;30:389-395. [PMID: 25168607 DOI: 10.1111/jgh.12725] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 8.2] [Reference Citation Analysis]
175 Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol. 2015;7:1685-1693. [PMID: 26140088 DOI: 10.4254/wjh.v7.i12.1685] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
176 Wu SJ, Yan HD, Zheng ZX, Shi KQ, Wu FL, Xie YY, Fan YC, Ye BZ, Huang WJ, Chen YP, Zheng MH. Establishment and validation of ALPH-Q score to predict mortality risk in patients with acute-on-chronic hepatitis B liver failure: a prospective cohort study. Medicine (Baltimore). 2015;94:e403. [PMID: 25590846 DOI: 10.1097/md.0000000000000403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
177 Solbach P, Höner zu Siederdissen C, Wellhöner F, Richter N, Heidrich B, Lenzen H, Kerstin P, Hueper K, Manns MP, Wedemeyer H, Jaeckel E. Automated low-flow ascites pump in a real-world setting: complications and outcomes. European Journal of Gastroenterology & Hepatology 2018;30:1082-9. [DOI: 10.1097/meg.0000000000001149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
178 Prié D, Forand A, Francoz C, Elie C, Cohen I, Courbebaisse M, Eladari D, Lebrec D, Durand F, Friedlander G. Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list. PLoS One 2013;8:e66182. [PMID: 23825530 DOI: 10.1371/journal.pone.0066182] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
179 Storm C, Bernhardt W, Schaeffner E, Neuhaus R, Pascher A, Neuhaus P, Hasper D, Frei U, Kahl A. Immediate Recovery of Renal Function After Orthotopic Liver Transplantation in a Patient With Hepatorenal Syndrome Requiring Hemodialysis for More Than 8 Months. Transplantation Proceedings 2007;39:544-6. [DOI: 10.1016/j.transproceed.2006.12.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
180 Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet. 1997;349:697-698. [PMID: 9078203 DOI: 10.1016/s0140-6736(97)24010-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
181 Powell LW. Overview: Liver disease and transplantation. Journal of Gastroenterology and Hepatology 2009;24:S97-S104. [DOI: 10.1111/j.1440-1746.2009.06079.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
182 Turban S, Thuluvath PJ, Atta MG. Hepatorenal syndrome. World J Gastroenterol 2007;13:4046-55. [PMID: 17696221 DOI: 10.3748/wjg.v13.i30.4046] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
183 Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study. Dig Liver Dis 2009;41:298-302. [PMID: 19158001 DOI: 10.1016/j.dld.2008.09.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
184 Saab S, Nieto J, Ly D, Runyon B, Saab S. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd004889] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
185 Long B, Koyfman A. The emergency medicine evaluation and management of the patient with cirrhosis. The American Journal of Emergency Medicine 2018;36:689-98. [DOI: 10.1016/j.ajem.2017.12.047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
186 Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018;10:55-71. [PMID: 30013405 DOI: 10.2147/hmer.s136578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
187 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
188 Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, Peck-Radosavljevic M, Gridelli B, Bosch J. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl. 2007;13:1174-1180. [PMID: 17663415 DOI: 10.1002/lt.21197] [Cited by in Crossref: 162] [Cited by in F6Publishing: 133] [Article Influence: 11.6] [Reference Citation Analysis]
189 Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol. 2005;42:700-706. [PMID: 15826720 DOI: 10.1016/j.jhep.2004.12.022] [Cited by in Crossref: 152] [Cited by in F6Publishing: 129] [Article Influence: 9.5] [Reference Citation Analysis]
190 Kalambokis G, Fotopoulos A, Economou M, Tsianos EV. Octreotide in the treatment of refractory ascites of cirrhosis. Scandinavian Journal of Gastroenterology 2009;41:118-21. [DOI: 10.1080/00365520510024043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
191 Altun R, Korkmaz M, Yıldırım E, Öcal S, Akbaş E, Selçuk H. Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response? Springerplus 2015;4:806. [PMID: 26722626 DOI: 10.1186/s40064-015-1625-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
192 Jenq CC, Tsai MH, Tian YC, Lin CY, Yang C, Liu NJ, Lien JM, Chen YC, Fang JT, Chen PC, Yang CW. RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients. Intensive Care Med. 2007;33:1921-1930. [PMID: 17605129 DOI: 10.1007/s00134-007-0760-6] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 6.9] [Reference Citation Analysis]
193 Yoshikawa T, Nomi T, Hokuto D, Yasuda S, Kawaguchi C, Yamada T, Kanehiro H, Nakajima Y. Risk Factors for Postoperative Ascites in Patients Undergoing Liver Resection for Hepatocellular Carcinoma. World J Surg 2017;41:2095-100. [PMID: 28332060 DOI: 10.1007/s00268-017-4003-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
194 Karvellas CJ, Bagshaw SM. Advances in management and prognostication in critically ill cirrhotic patients. Curr Opin Crit Care. 2014;20:210-217. [PMID: 24514101 DOI: 10.1097/mcc.0000000000000067] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
195 Kathpalia P, Bhatia A, Robertazzi S, Ahn J, Cohen SM, Sontag S, Luke A, Durazo-arvizu R, Pillai AA. Indwelling peritoneal catheters in patients with cirrhosis and refractory ascites: Peritoneal drains for refractory ascites. Intern Med J 2015;45:1026-31. [DOI: 10.1111/imj.12843] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
196 Baraldi O, Valentini C, Donati G, Comai G, Cuna V, Capelli I, Angelini ML, Moretti MI, Angeletti A, Piscaglia F. Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol. 2015;4:511-520. [PMID: 26558188 DOI: 10.5527/wjn.v4.i5.511] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
197 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460. [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024] [Cited by in Crossref: 660] [Cited by in F6Publishing: 457] [Article Influence: 220.0] [Reference Citation Analysis]
198 Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, Solá E, Baccaro ME, Terra C, Arroyo V. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51:219-226. [PMID: 19877168 DOI: 10.1002/hep.23283] [Cited by in Crossref: 135] [Cited by in F6Publishing: 108] [Article Influence: 12.3] [Reference Citation Analysis]
199 Cura M, Haskal Z, Lopera J. Diagnostic and interventional radiology for Budd-Chiari syndrome. Radiographics. 2009;29:669-681. [PMID: 19448109 DOI: 10.1148/rg.293085056] [Cited by in Crossref: 72] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
200 Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010;25:880-5. [PMID: 20074149 DOI: 10.1111/j.1440-1746.2009.06132.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 59] [Article Influence: 7.2] [Reference Citation Analysis]
201 Sandhu BS, Sanyal AJ. Management of ascites in cirrhosis. Clin Liver Dis. 2005;9:715-732, viii. [PMID: 16207572 DOI: 10.1016/j.cld.2005.07.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
202 Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE Jr. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021;298:493-504. [PMID: 33497318 DOI: 10.1148/radiol.2021201960] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Trivedi PS, Rochon PJ, Durham JD, Ryu RK. National Trends and Outcomes of Transjugular Intrahepatic Portosystemic Shunt Creation Using the Nationwide Inpatient Sample. Journal of Vascular and Interventional Radiology 2016;27:838-45. [DOI: 10.1016/j.jvir.2015.12.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
204 Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Reddy KR. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl 2005;11:1048-55. [PMID: 16123966 DOI: 10.1002/lt.20445] [Cited by in Crossref: 125] [Cited by in F6Publishing: 108] [Article Influence: 7.8] [Reference Citation Analysis]
205 Thomson MJ, Taylor A, Sharma P, Lok AS, Tapper EB. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis. Dig Dis Sci 2020;65:1539-48. [PMID: 31571102 DOI: 10.1007/s10620-019-05858-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
206 Barahona-Garrido J, Hernández-Calleros J, Téllez-Avila FI, Chávez-Tapia NC, Remes-Troche JM, Torre A. Bacterial meningitis in cirrhotic patients: case series and description of the prognostic role of acute renal failure. J Clin Gastroenterol. 2010;44:e218-e223. [PMID: 20453662 DOI: 10.1097/mcg.0b013e3181d88d53] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
207 Castro R, Deisanti D, Seva-pereira T, Almeida J, Yamanaka A, Boin I, Soares E. Survival Before and After Model for End-stage Liver Disease Score Introduction on the Brazilian Liver Transplant Waiting List. Transplantation Proceedings 2010;42:412-6. [DOI: 10.1016/j.transproceed.2010.01.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
208 Riggio O, Masini A, Efrati C, Merli M. TIPS: Refractory Ascites and Encephalopathy. In: Rossi P, Ricci P, Broglia L, editors. Portal Hypertension. Berlin: Springer Berlin Heidelberg; 2000. pp. 297-303. [DOI: 10.1007/978-3-642-57116-9_26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
209 Hsieh P, Ueng SW, Lee MS, Shih H, Huang K. Prosthetic hip infection in patients with liver cirrhosis: an outcome analysis. International Journal of Infectious Diseases 2010;14:e1054-9. [DOI: 10.1016/j.ijid.2010.06.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
210 Thomas MN, Sauter GH, Gerbes AL, Stangl M, Schiergens TS, Angele M, Werner J, Guba M. Automated low flow pump system for the treatment of refractory ascites: a single-center experience. Langenbecks Arch Surg. 2015;400:979-983. [PMID: 26566989 DOI: 10.1007/s00423-015-1356-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
211 Harambat J, Ranchin B, Dubourg L, Liutkus A, Hadj-Haïssa A, Rivet C, Boillot O, Lachaux A, Cochat P. Renal function in pediatric liver transplantation: a long-term follow-up study. Transplantation. 2008;86:1028-1034. [PMID: 18946339 DOI: 10.1097/tp.0b013e318187748f] [Cited by in Crossref: 48] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
212 Cárdenas A, Arroyo V. Hepatorenal syndrome. Annals of Hepatology 2003;2:23-9. [DOI: 10.1016/s1665-2681(19)32154-4] [Cited by in Crossref: 18] [Article Influence: 1.0] [Reference Citation Analysis]
213 Robertson M, Majumdar A, Garrett K, Rumler G, Gow P, Testro A. Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation. Hepatology 2014;60:2125-6. [PMID: 24687396 DOI: 10.1002/hep.27154] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
214 Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002;14:1363-1368. [PMID: 12468959 DOI: 10.1097/00042737-200212000-00013] [Cited by in Crossref: 108] [Cited by in F6Publishing: 82] [Article Influence: 6.0] [Reference Citation Analysis]
215 Ohashi N, Tsuji N, Naito Y, Iwakura T, Isobe S, Ono M, Fujikura T, Tsuji T, Sakao Y, Yasuda H, Kawamura K, Sakaguchi T, Kato A, Fujigaki Y. Relationship between urinary fractional excretion of sodium and life prognosis in liver cirrhosis patients. Hepatol Res 2013;43:1156-62. [PMID: 23387436 DOI: 10.1111/hepr.12068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
216 Rezayat KA, Zeraati AA, Pezeshki Rad M, Chogan J, Davoudian N, Akhavan Rezayat A, Hoseini SM. Impact of Propranolol on Preventing Renal Dysfunction in Patients with Cirrhosis. Middle East J Dig Dis 2017;9:206-11. [PMID: 29255578 DOI: 10.15171/mejdd.2017.75] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
217 Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL. Terlipressin vs other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017;9:CD011532. [PMID: 28953318 DOI: 10.1002/14651858.cd011532.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
218 Gunsar F, Raimondo ML, Jones S, Terreni N, Wong C, Patch D, Sabin C, Burroughs AK. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther. 2006;24:563-572. [PMID: 16827812 DOI: 10.1111/j.1365-2036.2006.03003.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 98] [Article Influence: 7.5] [Reference Citation Analysis]
219 Seckin Y, Yigit A, Yesilada E, Gulbay G, Cagin YF, Gozukara H, Bılgıc Y, Yildirim O, Turkoz Y, Aksungur Z. Association of eNOS Gene Polymorphisms G894T and T-786C with Risk of Hepatorenal Syndrome. Gastroenterol Res Pract 2016;2016:2579626. [PMID: 27594880 DOI: 10.1155/2016/2579626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
220 Vaccaro F, Giorgi A, Riggio O, De Santis A, Laviano A, Rossi-fanelli F. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. Digestive and Liver Disease 2003;35:503-6. [DOI: 10.1016/s1590-8658(03)00225-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
221 Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005;20:1813-20. [PMID: 15956066 DOI: 10.1093/ndt/gfh930] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
222 Capling RK, Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail. 2004;26:563-568. [PMID: 15526916 DOI: 10.1081/jdi-200035988] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
223 Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology. 2000;118:565-572. [PMID: 10702208 DOI: 10.1016/s0016-5085(00)70263-0] [Cited by in Crossref: 65] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
224 Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis 2016;68:381-91. [PMID: 26994685 DOI: 10.1053/j.ajkd.2016.02.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
225 Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, Morando F, Gola E, Frigo AC, Gatta A, Angeli P. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 2013;59:482-489. [PMID: 23665185 DOI: 10.1016/j.jhep.2013.03.039] [Cited by in Crossref: 151] [Cited by in F6Publishing: 117] [Article Influence: 18.9] [Reference Citation Analysis]
226 Gentilini P, Laffi G, Villa GL, Romanelli RG, Blendis LM. Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? Journal of Hepatology 1999;31:1087. [DOI: 10.1016/s0168-8278(99)80324-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
227 Rey R M, Delgado AF, De Zubiria A, Pinto R, De la Hoz-Valle JA, Pérez-Riveros ED, Ardila G, Sierra-Arango F. Prevalence and short-term outcome of hepatorenal syndrome: A 9-year experience in a high-complexity hospital in Colombia. PLoS One 2020;15:e0239834. [PMID: 33079947 DOI: 10.1371/journal.pone.0239834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
228 Nietsch HH. Management of Portal Hypertension: . Journal of Clinical Gastroenterology 2005;39:232-6. [DOI: 10.1097/01.mcg.0000152783.22266.35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
229 Fleming JN, Abou Abbass A. Hepatorenal syndrome: a comprehensive overview for the critical care nurse. Crit Care Nurs Clin North Am 2010;22:351-68. [PMID: 20691386 DOI: 10.1016/j.ccell.2010.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
230 Safi W, Rauscher I, Umgelter A. Contrast-induced acute kidney injury in cirrhotic patients. A retrospective analysis. Ann Hepatol 2015;14:895-901. [PMID: 26436362 DOI: 10.5604/16652681.1171779] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
231 Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22. [PMID: 9696006 DOI: 10.1002/hep.510280219] [Cited by in Crossref: 268] [Cited by in F6Publishing: 199] [Article Influence: 11.7] [Reference Citation Analysis]
232 Kalambokis G, Milionis H, Elisaf M, Tsianos EV. Terlipressin avoids hemodialysis in the treatment of refractory hyperkalemia associated with renal dysfunction in cirrhosis. Am J Med 2005;118:1051-2. [PMID: 16164896 DOI: 10.1016/j.amjmed.2005.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
233 Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med 2020;8:220-36. [PMID: 33511049 DOI: 10.2478/jtim-2020-0035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, Graupera I, Ariza X, Pereira G, Alfaro I. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59:474-481. [PMID: 23669284 DOI: 10.1016/j.jhep.2013.04.036] [Cited by in Crossref: 166] [Cited by in F6Publishing: 132] [Article Influence: 20.8] [Reference Citation Analysis]
235 Jun BG, Lee WC, Jang JY, Jeong SW, Kim YD, Cheon GJ, Lee YN, Kim SG, Kim YS, Cho YS, Lee SH, Kim HS. Follow-up Creatinine Level Is an Important Predictive Factor of In-hospital Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. J Korean Med Sci 2018;33:e99. [PMID: 29542304 DOI: 10.3346/jkms.2018.33.e99] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
236 De las Heras D, Fernández J, Ginès P, Cárdenas A, Ortega R, Navasa M, Barberá JA, Calahorra B, Guevara M, Bataller R. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology. 2003;38:452-459. [PMID: 12883490 DOI: 10.1053/jhep.2003.50304] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
237 Subedi A, Suresh Kumar VC, Sharma Subedi A, Sapkota B. A Review of Hepatorenal Syndrome. Cureus 2021;13:e16084. [PMID: 34367745 DOI: 10.7759/cureus.16084] [Reference Citation Analysis]
238 Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e0431. [PMID: 29668606 DOI: 10.1097/md.0000000000010431] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 6.7] [Reference Citation Analysis]
239 Burgos AC, Thornburg B. Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites: Review and Update of the Literature. Semin Intervent Radiol 2018;35:165-8. [PMID: 30087519 DOI: 10.1055/s-0038-1661347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
240 Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, Soni RK. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci. 2012;57:1664-1671. [PMID: 22388710 DOI: 10.1007/s10620-012-2097-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
241 Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int. 2004;24:210-215. [PMID: 15189271 DOI: 10.1111/j.1478-3231.2004.00911.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
242 Grewal P, Martin P. Pretransplant management of the cirrhotic patient. Clin Liver Dis 2007;11:431-49. [PMID: 17606216 DOI: 10.1016/j.cld.2007.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
243 Figueiredo A, Romero-Bermejo F, Perdigoto R, Marcelino P. The end-organ impairment in liver cirrhosis: appointments for critical care. Crit Care Res Pract. 2012;2012:539412. [PMID: 22666568 DOI: 10.1155/2012/539412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
244 Han E, Cho Y, Kim KW, Lee YH, Kang ES, Cha BS, Lee BW. Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. Medicine (Baltimore) 2020;99:e21038. [PMID: 32871978 DOI: 10.1097/MD.0000000000021038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
245 Leithead JA, Rajoriya N, Tehami N, Hodson J, Gunson BK, Tripathi D, Ferguson JW. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2015;64:1111-9. [DOI: 10.1136/gutjnl-2013-306502] [Cited by in Crossref: 112] [Cited by in F6Publishing: 75] [Article Influence: 16.0] [Reference Citation Analysis]
246 Sabri M, Saps M, Peters JM. Pathophysiology and management of pediatric ascites. Curr Gastroenterol Rep. 2003;5:240-246. [PMID: 12734047 DOI: 10.1007/s11894-003-0026-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
247 Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012;9:CD005162. [PMID: 22972083 DOI: 10.1002/14651858.cd005162.pub3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
248 Gerth HU, Pohlen M, Thölking G, Pavenstädt H, Brand M, Wilms C, Hüsing-Kabar A, Görlich D, Kabar I, Schmidt HH. Molecular adsorbent recirculating system (MARS) in acute liver injury and graft dysfunction: Results from a case-control study. PLoS One 2017;12:e0175529. [PMID: 28403210 DOI: 10.1371/journal.pone.0175529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
249 Solà E, Ginès P. Assessment of acute kidney injury at hospital admission in cirrhosis: estimating baseline serum creatinine is not the answer. Liver Int 2015;35:2079-81. [PMID: 26053461 DOI: 10.1111/liv.12883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
250 Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, Selby R. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl. 2012;18:539-548. [PMID: 22250075 DOI: 10.1002/lt.23384] [Cited by in Crossref: 97] [Cited by in F6Publishing: 74] [Article Influence: 10.8] [Reference Citation Analysis]
251 Sarangapani A, Shanmugam C, Kalyanasundaram M, Rangachari B, Thangavelu P, Subbarayan JK. Noninvasive prediction of large esophageal varices in chronic liver disease patients. Saudi J Gastroenterol. 2010;16:38-42. [PMID: 20065573 DOI: 10.4103/1319-3767.58767] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
252 Borges de Santana V, Bertocco de Paiva Haddad L, Morgado Conte T, Cortez Rizzon A, Miranda Barbosa V, Shield W, Andraus W, Augusto Carneiro D’albuquerque L. MELD Score and Albumin Replacement Are Related to Higher Costs During Management of Patients With Refractory Ascites. Transplantation Proceedings 2014;46:1760-3. [DOI: 10.1016/j.transproceed.2014.05.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
253 Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, Izumi N. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS One 2017;12:e0174649. [PMID: 28362879 DOI: 10.1371/journal.pone.0174649] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
254 Millwala F, Nguyen GC, Thuluvath PJ. Outcomes of patients with cirrhosis undergoing non-hepatic surgery: risk assessment and management. World J Gastroenterol. 2007;13:4056-4063. [PMID: 17696222 DOI: 10.3748/wjg.v13.i30.4056] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
255 Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011;17:1328-1332. [PMID: 21837734 DOI: 10.1002/lt.22395] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
256 Kozaki K, IInuma M, Takagi T, Fukuda T, Sanpei T, Terunuma Y, Yatabe Y, Akano K. Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis. Ther Apher Dial. 2016;20:376-382. [PMID: 27523078 DOI: 10.1111/1744-9987.12469] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
257 Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818-824. [PMID: 17854593 DOI: 10.1053/j.gastro.2007.06.065] [Cited by in Crossref: 466] [Cited by in F6Publishing: 329] [Article Influence: 33.3] [Reference Citation Analysis]
258 Leithead JA, Tariciotti L, Gunson B, Holt A, Isaac J, Mirza DF, Bramhall S, Ferguson JW, Muiesan P. Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury. Am J Transplant. 2012;12:965-975. [PMID: 22226302 DOI: 10.1111/j.1600-6143.2011.03894.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 9.6] [Reference Citation Analysis]
259 Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites. World J Gastroenterol 2019;25:3738-52. [PMID: 31391769 DOI: 10.3748/wjg.v25.i28.3738] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
260 Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689-1697. [PMID: 18557715 DOI: 10.1111/j.1572-0241.2008.01828.x] [Cited by in Crossref: 162] [Cited by in F6Publishing: 128] [Article Influence: 12.5] [Reference Citation Analysis]
261 Misra VL, Vuppalanchi R, Jones D, Hamman M, Kwo PY, Kahi C, Chalasani N. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. Aliment Pharmacol Ther 2010;32:1044-50. [PMID: 20937051 DOI: 10.1111/j.1365-2036.2010.04426.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
262 Umbro I, Tinti F, Mordenti M, Rossi M, Ianni S, Pugliese F, Ruberto F, Ginanni Corradini S, Nofroni I, Poli L. Model for end-stage liver disease score versus simplified acute physiology score criteria in acute renal failure after liver transplantation. Transplant Proc. 2011;43:1139-1141. [PMID: 21620072 DOI: 10.1016/j.transproceed.2011.02.045] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
263 Lee JP, Heo NJ, Joo KW, Yi NJ, Suh KS, Moon KC, Kim SG, Kim YS. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant. 2010;25:2772-2785. [PMID: 20207711 DOI: 10.1093/ndt/gfq093] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
264 Yu AS, Hu K. MANAGEMENT OF ASCITES. Clinics in Liver Disease 2001;5:541-68. [DOI: 10.1016/s1089-3261(05)70177-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
265 Ginès P. Hepatorenal syndrome, pharmacological therapy, and liver transplantation. Liver Transpl 2011;17:1244-6. [DOI: 10.1002/lt.22433] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
266 Gupta K, Bhurwal A, Law C, Ventre S, Minacapelli CD, Kabaria S, Li Y, Tait C, Catalano C, Rustgi VK. Acute kidney injury and hepatorenal syndrome in cirrhosis. World J Gastroenterol 2021;27:3984-4003. [PMID: 34326609 DOI: 10.3748/wjg.v27.i26.3984] [Reference Citation Analysis]
267 Chalasani N, Gorski JC, Horlander JC, Craven R, Hoen H, Maya J, Brater DC. Effects of Albumin/Furosemide Mixtures on Responses to Furosemide in Hypoalbuminemic Patients. JASN 2001;12:1010-6. [DOI: 10.1681/asn.v1251010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
268 Hou W, Sanyal AJ. Ascites: diagnosis and management. Med Clin North Am. 2009;93:801-17, vii. [PMID: 19577115 DOI: 10.1016/j.mcna.2009.03.007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
269 Sharma P, Rakela J. Management of pre-liver transplantation patient?Part 2. Liver Transpl 2005;11:249-60. [DOI: 10.1002/lt.20379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
270 Arteel G, Marsano L, Mendez C, Bentley F, Mcclain CJ. Advances in alcoholic liver disease. Best Practice & Research Clinical Gastroenterology 2003;17:625-47. [DOI: 10.1016/s1521-6918(03)00053-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
271 Cárdenas A, Ginès P. Management of Refractory Ascites. Clinical Gastroenterology and Hepatology 2005;3:1187-91. [DOI: 10.1016/s1542-3565(05)00861-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
272 Pham PT, Pham PT, Wilkinson AH. THE KIDNEY IN LIVER TRANSPLANTATION. Clinics in Liver Disease 2000;4:567-90. [DOI: 10.1016/s1089-3261(05)70127-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
273 Kim JH. What we know about paracentesis induced circulatory dysfunction? Clin Mol Hepatol. 2015;21:349-351. [PMID: 26770922 DOI: 10.3350/cmh.2015.21.4.349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
274 Anand BS. Drug Treatment of the Complications of Cirrhosis in the Older Adult: . Drugs & Aging 2001;18:575-85. [DOI: 10.2165/00002512-200118080-00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
275 Morando F, Rosi S, Gola E, Nardi M, Piano S, Fasolato S, Stanco M, Cavallin M, Romano A, Sticca A, Caregaro L, Gatta A, Angeli P. Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. Liver Int. 2015;35:1508-1515. [PMID: 24811138 DOI: 10.1111/liv.12583] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
276 Suneja M, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011. Int J Nephrol 2016;2016:8419719. [PMID: 27144022 DOI: 10.1155/2016/8419719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
277 Italian Association for the Study of the Liver (AISF)., Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis. Dig Liver Dis 2016;48:4-15. [PMID: 26802734 DOI: 10.1016/j.dld.2015.11.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
278 Uriz J, Cárdenas A, Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Best Practice & Research Clinical Gastroenterology 2000;14:927-43. [DOI: 10.1053/bega.2000.0139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
279 Kamath PS, Mckusick MA. 8 Transjugular intrahepatic portosystemic shunts (TIPS). Baillière's Clinical Gastroenterology 1997;11:327-49. [DOI: 10.1016/s0950-3528(97)90043-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
280 Paz LN, Dias CS, Carvalho VMP, Muramoto C, Estrela-Lima A, Pinna MH. Unusual case of polyarthritis and hepatorenal syndrome associated with Leptospira interrogans infection in a dog: A case report. Res Vet Sci 2021;134:186-90. [PMID: 33388616 DOI: 10.1016/j.rvsc.2020.12.006] [Reference Citation Analysis]
281 Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. Journal of Hepatology 2015;63:1272-84. [DOI: 10.1016/j.jhep.2015.07.004] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 45.3] [Reference Citation Analysis]
282 Rosado B, Kamath PS. Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl. 2003;9:207-217. [PMID: 12619016 DOI: 10.1053/jlts.2003.50045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
283 Bass M. Fluid and Electrolyte Management of Ascites in Patients with Cirrhosis. Critical Care Nursing Clinics of North America 1998;10:459-67. [DOI: 10.1016/s0899-5885(18)30191-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
284 Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012;27:34-41. [PMID: 22287700 DOI: 10.1093/ndt/gfr736] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
285 Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ 2019;22:421-9. [PMID: 30724682 DOI: 10.1080/13696998.2019.1580201] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
286 Link BC, Ziske CG, Schepke M, Schmidt-Wolf IG, Sauerbruch T. Total ascitic fluid leukocyte count for reliable exclusion of spontaneous bacterial peritonitis in patients with ascites. Eur J Gastroenterol Hepatol. 2006;18:181-186. [PMID: 16394800 DOI: 10.1097/00042737-200602000-00011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
287 Leithead JA, MacKenzie SM, Ferguson JW, Hayes PC. Is estimated glomerular filtration rate superior to serum creatinine in predicting mortality on the waiting list for liver transplantation? Transpl Int 2011;24:482-8. [PMID: 21362061 DOI: 10.1111/j.1432-2277.2011.01231.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
288 Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2006;CD005162. [PMID: 17054242 DOI: 10.1002/14651858.cd005162.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
289 Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol. 2002;17:739-747. [PMID: 12121502 DOI: 10.1046/j.1440-1746.2002.02778.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
290 Garbuzenko DV, Arefyev NO. Hepatic hydrothorax: An update and review of the literature. World J Hepatol. 2017;9:1197-1204. [PMID: 29152039 DOI: 10.4254/wjh.v9.i31.1197] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
291 Carstens J, Grønbaek H, Larsen HK, Pedersen EB, Vilstrup H. Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention. BMC Gastroenterol 2007;7:1. [PMID: 17257428 DOI: 10.1186/1471-230X-7-1] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
292 Patti R, Almasio PL, Buscemi S, Famà F, Craxì A, Di Vita G. Inguinal hernioplasty improves the quality of life in patients with cirrhosis. Am J Surg. 2008;196:373-378. [PMID: 18639226 DOI: 10.1016/j.amjsurg.2008.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
293 Lal BB, Alam S, Sood V, Rawat D, Khanna R. Profile, risk factors and outcome of acute kidney injury in paediatric acute-on-chronic liver failure. Liver Int 2018;38:1777-84. [PMID: 29325220 DOI: 10.1111/liv.13693] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
294 Legaz I, Navarro-Noguera E, Bolarín JM, García-Alonso AM, Luna Maldonado A, Mrowiec A, Campillo JA, Gimeno L, Moya-Quiles R, Álvarez-López Mdel R, Minguela Puras A, Miras M, Sánchez-Bueno F, Muro M. Epidemiology, Evolution, and Long-Term Survival of Alcoholic Cirrhosis Patients Submitted to Liver Transplantation in Southeastern Spain. Alcohol Clin Exp Res 2016;40:794-805. [PMID: 27012317 DOI: 10.1111/acer.13013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
295 Harrison PM. Management of patients with decompensated cirrhosis. Clin Med (Lond) 2015;15:201-3. [PMID: 25824076 DOI: 10.7861/clinmedicine.15-2-201] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
296 Executive Committee of the German Medical Association on the Recommendation of the Scientific Advisory Board. Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised. Transfus Med Hemother 2016;43:223-32. [PMID: 27403094 DOI: 10.1159/000446043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
297 Utako P, Emyoo T, Anothaisintawee T, Yamashiki N, Thakkinstian A, Sobhonslidsuk A. Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. Biomed Res Int 2018;2018:5362810. [PMID: 29992152 DOI: 10.1155/2018/5362810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
298 Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. Journal of Hepatology 2007;46:935-46. [DOI: 10.1016/j.jhep.2007.02.001] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 6.8] [Reference Citation Analysis]
299 Giannelli V, Roux O, Laouénan C, Manchon P, Ausloos F, Bachelet D, Rautou PE, Weiss E, Moreau R, Mebazaa A, Cohen-Solal A, Durand F, Francoz C. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol 2020;72:463-71. [PMID: 31622697 DOI: 10.1016/j.jhep.2019.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
300 Caly WR, Abreu RM, Bitelman B, Carrilho FJ, Ono SK. Clinical Features of Refractory Ascites in Outpatients. Clinics (Sao Paulo). 2017;72:405-410. [PMID: 28792999 DOI: 10.6061/clinics/2017(07)03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
301 Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J 2019;7:529-37. [PMID: 31065370 DOI: 10.1177/2050640619825719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
302 Simonetti RG, Perricone G, Nikolova D, Bjelakovic G, Gluud C. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. Cochrane Database Syst Rev 2019;6:CD004039. [PMID: 31251387 DOI: 10.1002/14651858.CD004039.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
303 Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood. 2010;116:335-342. [PMID: 20308604 DOI: 10.1182/blood-2009-11-253948] [Cited by in Crossref: 91] [Cited by in F6Publishing: 76] [Article Influence: 8.3] [Reference Citation Analysis]
304 Xing T, Zhong L, Chen D, Peng Z. Experience of Combined Liver-Kidney Transplantation for Acute-on-Chronic Liver Failure Patients With Renal Dysfunction. Transplantation Proceedings 2013;45:2307-13. [DOI: 10.1016/j.transproceed.2013.02.127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
305 Lee OJ, Yoon JH, Lee EJ, Kim HJ, Kim TH. Acute myopathy associated with liver cirrhosis. World J Gastroenterol 2006;12:2254-8. [PMID: 16610032 DOI: 10.3748/wjg.v12.i14.2254] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
306 Pateria P, Jeffrey GP, Garas G, Tibballs J, Ferguson J, Delriviere L, Huang Y, Adams LA, Macquillan G. Transjugular intrahepatic portosystemic shunt: Indications, complications, survival and its use as a bridging therapy to liver transplant in Western Australia. J Med Imaging Radiat Oncol 2017;61:441-7. [DOI: 10.1111/1754-9485.12563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
307 Tarquini R, Masini E, La Villa G, Barletta G, Novelli M, Mastroianni R, Romanelli RG, Vizzutti F, Santosuosso U, Laffi G. Increased plasma carbon monoxide in patients with viral cirrhosis and hyperdynamic circulation. Am J Gastroenterol 2009;104:891-7. [PMID: 19277027 DOI: 10.1038/ajg.2009.2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
308 Yeboah MM, Hye Khan MA, Chesnik MA, Skibba M, Kolb LL, Imig JD. Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis. Nephrol Dial Transplant 2018;33:1333-43. [PMID: 29361048 DOI: 10.1093/ndt/gfx354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
309 Xie YD, Feng B, Gao Y, Wei L. Characteristics of alcoholic liver disease and predictive factors for mortality of patients with alcoholic cirrhosis. Hepatobiliary Pancreat Dis Int 2013;12:594-601. [PMID: 24322744 DOI: 10.1016/s1499-3872(13)60094-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
310 Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol 2015;15:167. [PMID: 26606982 DOI: 10.1186/s12876-015-0389-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
311 Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014;59:1532-1542. [PMID: 23744636 DOI: 10.1002/hep.26556] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 9.3] [Reference Citation Analysis]
312 Galal GM, Amin NF, Abdel Hafeez HA, El-Baz MA. Can serum fibrosis markers predict medium/large oesophageal varices in patients with liver cirrhosis? Arab J Gastroenterol 2011;12:62-7. [PMID: 21684475 DOI: 10.1016/j.ajg.2011.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
313 Fortune B, Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf). 2017;5:104-112. [PMID: 28533908 DOI: 10.1093/gastro/gox010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
314 Thalheimer U, Leandro G, Samonakis DN, Triantos CK, Senzolo M, Fung K, Davies N, Patch D, Burroughs AK. TIPS for refractory ascites: a single-centre experience. J Gastroenterol 2009;44:1089-95. [DOI: 10.1007/s00535-009-0099-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
315 Huo T, Lin H, Lee F, Hou M, Lee P, Wu J, Chang F, Lee S. Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score: Cirrhosis complications and survival risk. Liver International 2006;26:55-61. [DOI: 10.1111/j.1478-3231.2005.01190.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
316 Liu J, Zhou C, Shi Q, Ma J, Ye T, Zheng C, Feng G, Xiong B. Exploration of interventional therapy strategy for portal vein occlusion: a case series study. Eur J Gastroenterol Hepatol 2020;32:507-16. [PMID: 31658174 DOI: 10.1097/MEG.0000000000001586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Talwalkar JA, Kim WR, Rosen CB, Kamath PS, Wiesner RH. Effect of Minimal Listing Criteria on Waiting List Registration for Liver Transplantation: A Process-Outcome Analysis. Mayo Clinic Proceedings 2003;78:431-5. [DOI: 10.4065/78.4.431] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
318 Fagundes C, Pépin M, Guevara M, Barreto R, Casals G, Solà E, Pereira G, Rodríguez E, Garcia E, Prado V, Poch E, Jiménez W, Fernández J, Arroyo V, Ginès P. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. Journal of Hepatology 2012;57:267-73. [DOI: 10.1016/j.jhep.2012.03.015] [Cited by in Crossref: 129] [Cited by in F6Publishing: 101] [Article Influence: 14.3] [Reference Citation Analysis]
319 Moini M, Hoseini-asl MK, Taghavi SA, Sagheb MM, Nikeghbalian S, Salahi H, Bahador A, Motazedian M, Jafari P, Malek-hosseini SA. Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation: Hyponatremia and liver list mortality. Clinical Transplantation 2011;25:638-45. [DOI: 10.1111/j.1399-0012.2010.01350.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
320 Makhlouf NA, Mahran ZG, Sadek SH, Magdy DM, Makhlouf HA. Six-minute walk test before and after large-volume paracentesis in cirrhotic patients with refractory ascites: A pilot study. Arab J Gastroenterol 2019;20:81-5. [PMID: 31182343 DOI: 10.1016/j.ajg.2019.05.009] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Doyle MB, Subramanian V, Vachharajani N, Maynard E, Shenoy S, Wellen JR, Lin Y, Chapman WC. Results of Simultaneous Liver and Kidney Transplantation: A Single-Center Review. J Am Coll Surg. 2016;223:193-201. [PMID: 27103549 DOI: 10.1016/j.jamcollsurg.2016.04.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
322 Krag A, Møller S, Pedersen EB, Henriksen JH, Holstein-Rathlou NH, Bendtsen F. Impaired free water excretion in child C cirrhosis and ascites: relations to distal tubular function and the vasopressin system. Liver Int. 2010;30:1364-1370. [PMID: 20731774 DOI: 10.1111/j.1478-3231.2010.02319.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
323 Mattos ÂZ, Schacher FC, Mattos AA. Vasoconstrictors in hepatorenal syndrome - A critical review. Ann Hepatol 2019;18:287-90. [PMID: 31023616 DOI: 10.1016/j.aohep.2018.12.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
324 Garcia-Tsao G. Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Intervent Radiol 2005;22:278-86. [PMID: 21326706 DOI: 10.1055/s-2005-925554] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
325 Kaffy F, Borderie C, Chagneau C, Ripault MP, Larzillière I, Silvain C, Beauchant M. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. J Hepatol 1999;30:174. [PMID: 9927168 DOI: 10.1016/s0168-8278(99)80025-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
326 Lenaerts A, Codden T, Henry JP, Legros F, Ligny G. Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. Gastroenterol Clin Biol. 2005;29:1137-1142. [PMID: 16505759 DOI: 10.1016/s0399-8320(05)82178-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
327 Demirtaş S, Bozbaş A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clinica Chimica Acta 2001;311:81-9. [DOI: 10.1016/s0009-8981(01)00546-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
328 Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-43. [PMID: 12830007 DOI: 10.1053/jhep.2003.50276] [Cited by in Crossref: 97] [Cited by in F6Publishing: 69] [Article Influence: 5.4] [Reference Citation Analysis]
329 Stanley AJ, Forrest EH, Dabos K, Bouchier IA, Hayes PC. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites. Gastroenterology 1998;115:406-11. [DOI: 10.1016/s0016-5085(98)70207-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
330 Sàbat M, Guarner C, Soriano G, Bulbena O, Novella MT, Ortiz J, Ricart E, Villanueva C, Rosello J, Rodríguez J, Balanzó J. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998;43:2184-9. [PMID: 9790452 DOI: 10.1023/a:1026698001921] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
331 Ginès P. Diagnosis and treatment of hepatorenal syndrome. Baillieres Best Pract Res Clin Gastroenterol 2000;14:945-57. [PMID: 11139348 DOI: 10.1053/bega.2000.0140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
332 Demırtaş S, Can M, Yarpuzlu A. Hepatorenal syndrome. Clinical Chemistry and Laboratory Medicine (CCLM) 2006;44. [DOI: 10.1515/cclm.2006.062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
333 Ojeda-Yuren AS, Cerda-Reyes E, Herrero-Maceda MR, Castro-Narro G, Piano S. An Integrated Review of the Hepatorenal Syndrome. Ann Hepatol 2021;22:100236. [PMID: 32846202 DOI: 10.1016/j.aohep.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
334 Vincent F, Gonzalez F, Cohen Y. Hepatorenal syndromes in patients with end-stage liver failure admitted to the intensive care unit. Crit Care Med 2011;39:2386-7; author reply 2387. [PMID: 21926512 DOI: 10.1097/CCM.0b013e31822570ae] [Reference Citation Analysis]
335 Das K, Das K, Datta S, Pal S, Hembram JR, Dhali GK, Santra A, Chowdhury A. Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int. 2010;30:1033-1042. [PMID: 20492502 DOI: 10.1111/j.1478-3231.2010.02255.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
336 Runyon BA;  AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087-2107. [PMID: 19475696 DOI: 10.1002/hep.22853] [Cited by in Crossref: 567] [Cited by in F6Publishing: 419] [Article Influence: 47.3] [Reference Citation Analysis]
337 Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Olmo JAD, Rodrigo JM, Serra MA. Accumulation of Symmetric Dimethylarginine in Hepatorenal Syndrome. Exp Biol Med (Maywood) 2006;231:70-5. [DOI: 10.1177/153537020623100108] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
338 Dissegna D, Sponza M, Falleti E, Fabris C, Vit A, Angeli P, Piano S, Cussigh A, Cmet S, Toniutto P. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2019;31:626-632. [PMID: 30550458 DOI: 10.1097/meg.0000000000001342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
339 Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 2014;9:e107466. [PMID: 25203311 DOI: 10.1371/journal.pone.0107466] [Cited by in Crossref: 84] [Cited by in F6Publishing: 59] [Article Influence: 12.0] [Reference Citation Analysis]
340 Gentilini P, La Villa G. Liver–kidney pathophysiological interrelationships in liver diseases. Digestive and Liver Disease 2008;40:909-19. [DOI: 10.1016/j.dld.2008.05.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
341 D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology. 2005;129:1282-1293. [PMID: 16230081 DOI: 10.1053/j.gastro.2005.07.031] [Cited by in Crossref: 151] [Cited by in F6Publishing: 99] [Article Influence: 9.4] [Reference Citation Analysis]
342 Essa M, Sabry A, Abdelsameea E, Tharwa ES, Salama M. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. Eur J Gastroenterol Hepatol 2019;31:53-8. [PMID: 30247174 DOI: 10.1097/MEG.0000000000001250] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
343 Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864-871. [PMID: 10733541 DOI: 10.1053/he.2000.5852] [Cited by in Crossref: 1747] [Cited by in F6Publishing: 1470] [Article Influence: 83.2] [Reference Citation Analysis]
344 Arroyo V, Fernandez J. Relationship Between Systemic Hemodynamics, Renal Dysfunction, and Fluid Retention in Cirrhosis. Clin Liver Dis. 2013;2:120-122. [PMID: 30992841 DOI: 10.1002/cld.185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
345 Maurel P, Prémaud A, Carrier P, Essig M, Barbier L, Rousseau A, Silvain C, Causse X, Debette-Gratien M, Jacques J, Marquet P, Salamé E, Loustaud-Ratti V. Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First-year Post-Liver Transplantation. Transplantation 2021;105:1585-94. [PMID: 32639405 DOI: 10.1097/TP.0000000000003384] [Reference Citation Analysis]
346 Junghare M, Ibrahim HN. Not all types of acute kidney injury are equal in the setting of liver transplantation. Liver Transpl. 2012;18:507-508. [PMID: 22422672 DOI: 10.1002/lt.23428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
347 Kim TH, Ku DH, Um SH, Lee HA, Park SW, Chang JM, Yim SY, Suh SJ, Jung YK, Seo YS, Kim JH, Yim HJ, Yeon JE, Byun KS, Ahn H. How can we improve the performance of Model for End-Stage Liver Disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment?: Revised MELDNa score for HBV-decompensated LC. Journal of Gastroenterology and Hepatology 2018;33:1641-8. [DOI: 10.1111/jgh.14128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
348 Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology. 2008;134:1715-1728. [PMID: 18471549 DOI: 10.1053/j.gastro.2008.03.007] [Cited by in Crossref: 215] [Cited by in F6Publishing: 162] [Article Influence: 16.5] [Reference Citation Analysis]
349 Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med 2009;35:152-6. [DOI: 10.1007/s00134-008-1253-y] [Cited by in Crossref: 60] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
350 Hinz M, Wree A, Jochum C, Bechmann LP, Saner F, Gerbes AL, Gerken G, Canbay A. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Annals of Hepatology 2013;12:92-9. [DOI: 10.1016/s1665-2681(19)31390-0] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
351 Mackelaite L, Alsauskas ZC, Ranganna K. Renal failure in patients with cirrhosis. Med Clin North Am 2009;93:855-69, viii. [PMID: 19577118 DOI: 10.1016/j.mcna.2009.03.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
352 Kojima H, Tsujimoto T, Uemura M, Takaya A, Okamoto S, Ueda S, Nishio K, Miyamoto S, Kubo A, Minamino N, Kangawa K, Matsuo H, Fukui H. Significance of increased plasma adrenomedullin concentration in patients with cirrhosis. J Hepatol. 1998;28:840-846. [PMID: 9625320 DOI: 10.1016/s0168-8278(98)80235-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
353 Olivera-Martinez M, Sayles H, Vivekanandan R, D' Souza S, Florescu MC. Hepatorenal syndrome: are we missing some prognostic factors? Dig Dis Sci. 2012;57:210-214. [PMID: 21850494 DOI: 10.1007/s10620-011-1861-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
354 Hudson B, Hunt V, Waylen A, Mccune CA, Verne J, Forbes K. The incompatibility of healthcare services and end-of-life needs in advanced liver disease: A qualitative interview study of patients and bereaved carers. Palliat Med 2018;32:908-18. [DOI: 10.1177/0269216318756222] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
355 Gerbes AL, Gulberg V. Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol. 2006;12:516-519. [PMID: 16489662 DOI: 10.3748/wjg.v12.i4.516] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
356 Bashir MH, Iqbal S, Miller R, Singh J, Mubarak G, Likhtshteyn M, Bigajer E, Gallagher B, Hurairah A, Stefanov D, McFarlane SI, Ferstenberg R. Management and outcomes of hepatorenal syndrome at an urban academic medical center: a retrospective study. Eur J Gastroenterol Hepatol. 2019;31:1545-1549. [PMID: 31169567 DOI: 10.1097/meg.0000000000001462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
357 Cholongitas E, Senzolo M, Patch D, Shaw S, O’Beirne J, Burroughs AK. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality. Eur J Gastroenterol Hepatol. 2009;21:744-750. [PMID: 20160527 DOI: 10.1097/meg.0b013e328308bb9c] [Cited by in Crossref: 67] [Cited by in F6Publishing: 28] [Article Influence: 6.1] [Reference Citation Analysis]
358 Ginès P, Arroyo V. Is there still a need for albumin infusions to treat patients with liver disease? Gut 2000;46:588-90. [PMID: 10764695 DOI: 10.1136/gut.46.5.588] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
359 Spengler EK, Hunsicker LG, Zarei S, Zimmerman MB, Voigt MD. Transjugular intrahepatic portosystemic shunt does not independently increase risk of death in high model for end stage liver disease patients. Hepatol Commun 2017;1:460-8. [PMID: 29404473 DOI: 10.1002/hep4.1053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
360 Gelu-Simeon M, Bayan T, Ostos M, Boufassa F, Teicher E, Steyaert JM, Bertucci I, Anty R, Pageaux GP, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 PRETHEVIC study group. MELD Score Kinetics in Decompensated HIV+/HCV+ Patients: A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study). Medicine (Baltimore) 2015;94:e1239. [PMID: 26222860 DOI: 10.1097/MD.0000000000001239] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
361 Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40:802-810. [PMID: 15382176 DOI: 10.1002/hep.20405] [Cited by in Crossref: 22] [Cited by in F6Publishing: 111] [Article Influence: 1.3] [Reference Citation Analysis]
362 Jenq CC, Tsai MH, Tian YC, Chang MY, Lin CY, Lien JM, Chen YC, Fang JT, Chen PC, Yang CW. Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol. 2010;44:220-226. [PMID: 19636261 DOI: 10.1097/mcg.0b013e3181aabbcd] [Cited by in Crossref: 50] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
363 Umbro I, Tinti F, Fiacco F, Zavatto A, Piselli P, Di Natale V, Lai S, Vitarelli A, Corradini SG, Rossi M. Resistive index and MELD-Na: nephrologic monitoring in cirrhotic patients awaiting liver transplantation. Transplant Proc. 2013;45:2676-2679. [PMID: 24034022 DOI: 10.1016/j.transproceed.2013.07.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
364 Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol 2010;16:5139-47. [PMID: 21049548 DOI: 10.3748/wjg.v16.i41.5139] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
365 Cárdenas A, Ginès P. What’s new in the treatment of ascites and spontaneous bacterial peritonitis. Curr Gastroenterol Rep 2008;10:7-14. [DOI: 10.1007/s11894-008-0003-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
366 Mullen KD. Treatment of hepatorenal syndrome: lessons from the MARS trial. Hepatology 2002;35:492-3. [PMID: 11826426 DOI: 10.1053/jhep.2002.0350492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
367 Guevara M, Ginès P. Hepatorenal syndrome. Dig Dis. 2005;23:47-55. [PMID: 15920325 DOI: 10.1159/000084725] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
368 Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol. 2013;5:251-263. [PMID: 23717736 DOI: 10.4254/wjh.v5.i5.251] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
369 Solbach P, Höner Zu Siederdissen C, Taubert R, Ziegert S, Port K, Schneider A, Hueper K, Manns MP, Wedemeyer H, Jaeckel E. Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. Eur J Gastroenterol Hepatol 2017;29:539-46. [PMID: 28350743 DOI: 10.1097/MEG.0000000000000837] [Cited by in Crossref: 21] [Cited by in F6Publishing: 2] [Article Influence: 5.3] [Reference Citation Analysis]
370 Kramer L, Hörl WH. Hepatorenal syndrome. Seminars in Nephrology 2002;22:290-301. [DOI: 10.1053/snep.2002.33670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
371 Bhatia V, Lodha R. Intensive care management of children with acute liver failure. Indian J Pediatr. 2010;77:1288-1295. [PMID: 20799075 DOI: 10.1007/s12098-010-0167-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
372 Salerno F, Merli M, Cazzaniga M, Valeriano V, Rossi P, Lovaria A, Meregaglia D, Nicolini A, Lubatti L, Riggio O. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36:494-500. [PMID: 11943420 DOI: 10.1016/s0168-8278(01)00309-9] [Cited by in Crossref: 188] [Cited by in F6Publishing: 48] [Article Influence: 9.9] [Reference Citation Analysis]
373 Cardenas A, Ginès P. Management of complications of cirrhosis in patients awaiting liver transplantation. Journal of Hepatology 2005;42:S124-33. [DOI: 10.1016/j.jhep.2004.12.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
374 Elloumi H, Sabbah M, Bibani N, Trad D, Elleuch N, Gargouri D, Ouakaa A, Kharrat J. Effect of low dose albumin administration in spontaneous bacterial peritonitis on renal function and survival. Arab J Gastroenterol 2019;20:205-8. [PMID: 31759874 DOI: 10.1016/j.ajg.2019.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
375 Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, Salinas F, Donà S, Fagiuoli S, Sticca A. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45:223-229. [PMID: 17187409 DOI: 10.1002/hep.21443] [Cited by in Crossref: 198] [Cited by in F6Publishing: 152] [Article Influence: 14.1] [Reference Citation Analysis]
376 Tinti F, Lai S, Umbro I, Mordenti M, Barile M, Ginanni Corradini S, Rossi M, Poli L, Nofroni I, Berloco P, Mitterhofer A. Chronic Kidney Disease–Epidemiology Formula and Model for End-Stage Liver Disease Score in the Assessment of Renal Function in Candidates for Liver Transplantation. Transplantation Proceedings 2010;42:1229-32. [DOI: 10.1016/j.transproceed.2010.03.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
377 Munoz SJ. The hepatorenal syndrome. Med Clin North Am. 2008;92:813-37, viii-ix. [PMID: 18570944 DOI: 10.1016/j.mcna.2008.03.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
378 Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver. 2002;22 Suppl 2:5-13. [PMID: 12220296 DOI: 10.1002/lt.20236] [Cited by in Crossref: 214] [Cited by in F6Publishing: 171] [Article Influence: 11.9] [Reference Citation Analysis]
379 Esteva-Font C, Baccaro ME, Fernández-Llama P, Sans L, Guevara M, Ars E, Jiménez W, Arroyo V, Ballarín JA, Ginès P. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome. Hepatology. 2006;44:1555-1563. [PMID: 17133493 DOI: 10.1002/hep.21414] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
380 Quateen A, Pech M, Berg T, Bergk A, Podrabsky P, Felix R, Ricke J. Percutaneous Transjugular Direct Porto-caval Shunt in Patients with Budd-Chiari Syndrome. Cardiovasc Intervent Radiol 2006;29:565-70. [DOI: 10.1007/s00270-005-0103-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
381 Deschênes M, Dufresne M, Bui B, Fenyves D, Spahr L, Roy L, Lafortune M, Pomier-layrargues G. Predictors of Clinical Response to Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Cirrhotic Patients With Refractory Ascites. American Journal of Gastroenterology 1999;94:1361-5. [DOI: 10.1111/j.1572-0241.1999.01112.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis]
382 González-Abraldes J, García-Pagán JC, Bosch J. Nitric oxide and portal hypertension. Metab Brain Dis. 2002;17:311-324. [PMID: 12602508 DOI: 10.1023/a:1021957818240] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
383 Fox M, Fox J, Davies M. Diagnosis and management of chronic liver disease in older people. Rev Clin Gerontol 2011;21:1-15. [DOI: 10.1017/s0959259810000365] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
384 Gerbes AL, Huber E, Gülberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology. 2009;137:1179; author reply 1179-1181. [PMID: 19631603 DOI: 10.1053/j.gastro.2009.03.064] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
385 Hara M, Tanaka S, Torisu K, Matsukuma Y, Tsuchimoto A, Tokumoto M, Ooboshi H, Nakano T, Tsuruya K, Kitazono T. Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study. Clin Exp Nephrol 2021;25:822-34. [PMID: 33856608 DOI: 10.1007/s10157-020-02018-z] [Reference Citation Analysis]
386 Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis. 2011;58:928-938. [PMID: 21962618 DOI: 10.1053/j.ajkd.2011.07.017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
387 Takaya H, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, Morioka C, Ishizashi H, Hori Y, Fujimoto M, Tsujimoto T, Kawaratani H, Toyohara M, Kurumatani N, Fukui H. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score. Hepatol Res 2012;42:459-72. [PMID: 22292786 DOI: 10.1111/j.1872-034X.2011.00950.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
388 Tsochatzis EA, Gerbes AL. Diagnosis and treatment of ascites. J Hepatol. 2017;67:184-185. [PMID: 28119010 DOI: 10.1016/j.jhep.2017.01.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
389 Moreau R, Lebrec D. Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Practice & Research Clinical Gastroenterology 2007;21:111-23. [DOI: 10.1016/j.bpg.2006.10.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
390 Abdel-Razik A, Mousa N, Abdelsalam M, Abdelwahab A, Tawfik M, Tawfik AM, Hasan AS, Elhelaly R, El-Wakeel N, Eldars W. Endothelin-1/Nitric Oxide Ratio as a Predictive Factor of Response to Therapy With Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome. Front Pharmacol 2020;11:9. [PMID: 32076410 DOI: 10.3389/fphar.2020.00009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
391 Cabezuelo JB, Ramírez P, Ríos A, Acosta F, Torres D, Sansano T, Pons JA, Bru M, Montoya M, Bueno FS. Risk factors of acute renal failure after liver transplantation. Kidney Int. 2006;69:1073-1080. [PMID: 16528257 DOI: 10.1038/sj.ki.5000216] [Cited by in Crossref: 198] [Cited by in F6Publishing: 160] [Article Influence: 13.2] [Reference Citation Analysis]
392 Ong JP, Sands M, Younossi ZM. Transjugular intrahepatic portosystemic shunts (TIPS): a decade later. J Clin Gastroenterol. 2000;30:14-28. [PMID: 10636206 DOI: 10.1097/00004836-200001000-00005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
393 Leithead JA, Armstrong MJ, Corbett C, Andrew M, Kothari C, Gunson BK, Mirza D, Muiesan P, Ferguson JW. Split liver transplant recipients do not have an increased frequency of acute kidney injury. Transpl Int 2014;27:1125-34. [DOI: 10.1111/tri.12376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
394 Harada N, Shirabe K, Ijichi H, Matono R, Uchiyama H, Yoshizumi T, Taketomi A, Soejima Y, Maehara Y. Acoustic radiation force impulse imaging predicts postoperative ascites resulting from curative hepatic resection for hepatocellular carcinoma. Surgery 2012;151:837-43. [PMID: 22386275 DOI: 10.1016/j.surg.2011.12.035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
395 Endo K, Iida T, Yagi S, Yoshizawa A, Fujimoto Y, Ogawa K, Ogura Y, Mori A, Kaido T, Uemoto S. Impact of preoperative uncontrollable hepatic hydrothorax and massive ascites in adult liver transplantation. Surg Today. 2014;44:2293-2299. [PMID: 24509883 DOI: 10.1007/s00595-014-0839-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
396 Fabrizi F, Messa P. Challenges in Renal Failure Treatment Before Liver Transplant. Clinics in Liver Disease 2017;21:303-19. [DOI: 10.1016/j.cld.2016.12.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
397 Nevens F, Bittencourt PL, Coenraad MJ, Ding H, Hou MC, Laterre PF, Mendizabal M, Ortiz-Olvera NX, Vorobioff JD, Zhang W, Angeli P. Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Dig Dis Sci 2019;64:1419-31. [PMID: 30684079 DOI: 10.1007/s10620-018-5448-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
398 Sofue K, Arai Y, Takeuchi Y, Fujiwara H, Tokue H, Sugimura K. Safety and efficacy of primary metallic biliary stent placement with tract embolization in patients with massive ascites: a retrospective analysis of 16 patients. J Vasc Interv Radiol 2012;23:521-7. [PMID: 22464717 DOI: 10.1016/j.jvir.2012.01.073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
399 Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013;38:345-354. [PMID: 24107793 DOI: 10.1159/000355540] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
400 Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology. 2006;43:385-394. [PMID: 16496352 DOI: 10.1002/hep.21094] [Cited by in Crossref: 98] [Cited by in F6Publishing: 72] [Article Influence: 6.5] [Reference Citation Analysis]
401 Kuiper JJ, de Man RA, van Buuren HR. Review article: Management of ascites and associated complications in patients with cirrhosis. Aliment Pharmacol Ther. 2007;26 Suppl 2:183-193. [PMID: 18081661 DOI: 10.1111/j.1365-2036.2007.03482.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
402 Li Y, He X, Pang H. A model to predict early hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt. Turk J Gastroenterol. 2019;30:702-707. [PMID: 31418414 DOI: 10.5152/tjg.2019.18485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
403 Vagefi PA, Qian JJ, Carlson DM, Aparici CM, Hirose R, Vincenti F, Wojciechowski D. Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans. Transpl Int 2013;26:471-6. [DOI: 10.1111/tri.12066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
404 Cicinnati VR, Yu Z, Klein CG, Sotiropoulos GC, Saner F, Malagó M, Frilling A, Gerken G, Broelsch CE, Beckebaum S. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther. 2007;26:1195-1208. [PMID: 17944734 DOI: 10.1111/j.1365-2036.2007.03466.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
405 Sanaka MR, Ong JP, Mullen KD. Challenges of designing hepatic encephalopathy treatment trials. Hepatology 2003;38:527-9. [DOI: 10.1002/hep.510380231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
406 Trawalé JM, Paradis V, Rautou PE, Francoz C, Escolano S, Sallée M, Durand F, Valla D, Lebrec D, Moreau R. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 2010;30:725-32. [PMID: 20040048 DOI: 10.1111/j.1478-3231.2009.02182.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 82] [Article Influence: 9.3] [Reference Citation Analysis]
407 Shah N, Silva RG, Kowalski A, Desai C, Lerma E. Hepatorenal syndrome. Dis Mon. 2016;62:364-375. [PMID: 27372112 DOI: 10.1016/j.disamonth.2016.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
408 Gadano A, Moreau R, Vachiery F, Soupison T, Yang S, Cailmail S, Sogni P, Hadengue A, Durand F, Valla D, Lebrec D. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. Journal of Hepatology 1997;26:1229-34. [DOI: 10.1016/s0168-8278(97)80456-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
409 Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther. 2017;45:593-603. [PMID: 28052382 DOI: 10.1111/apt.13912] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
410 Tandon P, Bain VG, Tsuyuki RT, Klarenbach S. Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther. 2007;25:1017-1028. [PMID: 17439502 DOI: 10.1111/j.1365-2036.2007.03303.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
411 Busk TM, Bendtsen F, Møller S. Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects.Expert Rev Gastroenterol Hepatol. 2016;10:1153-1161. [PMID: 27248461 DOI: 10.1080/17474124.2016.1196132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
412 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397-417. [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004] [Cited by in Crossref: 1002] [Cited by in F6Publishing: 779] [Article Influence: 91.1] [Reference Citation Analysis]
413 Salerno F, Monti V. Hepatorenal syndrome type 1 and bacterial infection: a catastrophic association in patients with cirrhosis. Hepatology. 2014;59:1239-1241. [PMID: 24425447 DOI: 10.1002/hep.27015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
414 Harrod-Kim P, Saad WE, Waldman D. Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites. J Vasc Interv Radiol. 2006;17:1605-1610. [PMID: 17057001 DOI: 10.1097/01.rvi.0000240651.38289.4b] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
415 Gerbes AL, Gülberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology. 1998;28:683-688. [PMID: 9731559 DOI: 10.1002/hep.510280313] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.0] [Reference Citation Analysis]
416 Rodriguez E, Henrique Pereira G, Solà E, Elia C, Barreto R, Pose E, Colmenero J, Fernandez J, Navasa M, Arroyo V. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transpl. 2015;21:1347-1354. [PMID: 26178066 DOI: 10.1002/lt.24210] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
417 Ginès P, Arroyo V, Rodès J. Pathophysiology, complications, and treatment of ascites. Clin Liver Dis 1997;1:129-55. [PMID: 15562674 DOI: 10.1016/s1089-3261(05)70261-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
418 Brensing KA, Raab P, Textor J, Görich J, Schiedermaier P, Strunk H, Paar D, Schepke M, Sudhop T, Spengler U, Schild H, Sauerbruch T. Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysis: . European Journal of Gastroenterology & Hepatology 2002;14:723-31. [DOI: 10.1097/00042737-200207000-00003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
419 Fábrega E, Berja A, García-unzueta MT, Guerra-ruiz A, Cobo M, López M, Bolado-carrancio A, Amado JA, Rodríguez-rey JC, Pons-romero F. Influence of aquaporin-1 gene polymorphism on water retention in liver cirrhosis. Scandinavian Journal of Gastroenterology 2011;46:1267-74. [DOI: 10.3109/00365521.2011.603161] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
420 Terra C, Mattos ÂZD, Pereira G, Farias AQ, Kondo M, Mattos AAD, Medeiros Filho JEMD, Strauss E, Dutra FRD, Mazza M, Lopes EP, Pereira TS, Schiavon LL, Carvalho Filho RJD, Fagundes C, Bittencourt PL. RECOMMENDATIONS OF THE BRAZILIAN SOCIETY OF HEPATOLOGY FOR THE MANAGEMENT OF ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS. Arq Gastroenterol 2018;55:314-20. [DOI: 10.1590/s0004-2803.201800000-71] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Rajesh S, George T, Philips CA, Ahamed R, Kumbar S, Mohan N, Mohanan M, Augustine P. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.World J Gastroenterol. 2020;26:5561-5596. [PMID: 33088154 DOI: 10.3748/wjg.v26.i37.5561] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
422 Assem M, Elsabaawy M, Abdelrashed M, Elemam S, Khodeer S, Hamed W, Abdelaziz A, El-Azab G. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int. 2016;10:377-385. [PMID: 26660707 DOI: 10.1007/s12072-015-9688-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
423 Sussman AN, Boyer TD. Management of refractory ascites and hepatorenal syndrome. Curr Gastroenterol Rep 2011;13:17-25. [PMID: 21080246 DOI: 10.1007/s11894-010-0156-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
424 Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, Burdick L. Humoral and cardiac effects of TIPS in cirrhotic patients with different “effective” blood volume. Hepatology. 2003;38:1370-1377. [PMID: 14647047 DOI: 10.1016/j.hep.2003.09.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
425 Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol. 2009;6:542-553. [PMID: 19652652 DOI: 10.1038/nrgastro.2009.127] [Cited by in Crossref: 127] [Cited by in F6Publishing: 95] [Article Influence: 10.6] [Reference Citation Analysis]
426 Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK. Terlipressin therapy for renal failure in cirrhosis. Eur J Gastroenterol Hepatol 2010;22:481-6. [PMID: 19952764 DOI: 10.1097/MEG.0b013e3283345524] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
427 Davis CL. Controversies in combined liver-kidney transplantation: indications and outcomes. Transplantation Reviews 2008;22:82-8. [DOI: 10.1016/j.trre.2007.03.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
428 Ling Q, Xu X, Wei Q, Liu X, Guo H, Zhuang L, Chen J, Xia Q, Xie H, Wu J. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. PLoS One. 2012;7:e30322. [PMID: 22291934 DOI: 10.1371/journal.pone.0030322] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
429 Briceño J, Ciria R, de la Mata M, Montero JL, Rufián S, López-cillero P. Extended criteria donors in liver transplant candidates with hepatorenal syndrome: Marginal liver grafts in hepatorenal syndrome. Clinical Transplantation 2011;25:E257-63. [DOI: 10.1111/j.1399-0012.2011.01402.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
430 Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G; International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531-537. [PMID: 25631669 DOI: 10.1136/gutjnl-2014-308874] [Cited by in Crossref: 202] [Cited by in F6Publishing: 149] [Article Influence: 33.7] [Reference Citation Analysis]
431 Gerbes AL, Gülberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002;50:106-10. [PMID: 11772976 DOI: 10.1136/gut.50.1.106] [Cited by in F6Publishing: 81] [Reference Citation Analysis]
432 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
433 Bagshaw SM, Bellomo R, Devarajan P, Johnson C, Karvellas CJ, Kutsiogiannis DJ, Mehta R, Pannu N, Romanovsky A, Sheinfeld G, Taylor S, Zappitelli M, Gibney RTN. Review article: Acute kidney injury in critical illness. Can J Anesth/J Can Anesth 2010;57:985-98. [DOI: 10.1007/s12630-010-9375-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
434 Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Katsaraki A, Tsianos EV. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites. Nephrol Dial Transplant. 2005;20:1623-1629. [PMID: 15886218 DOI: 10.1093/ndt/gfh871] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
435 Inoue Y, Kitada K, Fujii K, Kagota S, Tomioka A, Yamaguchi T, Yokohama K, Ohama H, Hamamoto H, Ishii M, Osumi W, Tsuchimoto Y, Terazawa T, Ogura T, Masubuchi S, Yamamoto M, Imoto A, Asai A, Komeda K, Fukunishi S, Hirokawa F, Goto M, Tanaka K, Okuda J, Higuchi K, Uchiyama K. The Relationship Between the Number of Ports and Surgical Outcomes in Laparoscopic Hepatectomy. Surg Laparosc Endosc Percutan Tech 2020;30:85-90. [PMID: 31876888 DOI: 10.1097/SLE.0000000000000750] [Reference Citation Analysis]
436 Piano S, Romano A, Di Pascoli M, Angeli P. Why and how to measure renal function in patients with liver disease. Liver Int. 2017;37 Suppl 1:116-122. [PMID: 28052631 DOI: 10.1111/liv.13305] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
437 Miyaaki H, Nakamura Y, Ichikawa T, Taura N, Miuma S, Shibata H, Honda T, Nakao K. Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance. Biomed Rep 2015;3:884-6. [PMID: 26623035 DOI: 10.3892/br.2015.521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
438 Song T, Rössle M, He F, Liu F, Guo X, Qi X. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. Dig Liver Dis 2018;50:323-30. [PMID: 29422242 DOI: 10.1016/j.dld.2018.01.123] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
439 Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7. [PMID: 10347109 DOI: 10.1002/hep.510290629] [Cited by in Crossref: 362] [Cited by in F6Publishing: 263] [Article Influence: 16.5] [Reference Citation Analysis]
440 Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura M, Kawaratani H, Terai S, Yoshiji H, Uto H, Sakaida I, Izumi N, Okita K, Koike K. Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol 2018;53:258-68. [PMID: 28664229 DOI: 10.1007/s00535-017-1366-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
441 Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol. 2012;56 Suppl 1:S13-S24. [PMID: 22300462 DOI: 10.1016/s0168-8278(12)60003-8] [Cited by in Crossref: 86] [Cited by in F6Publishing: 26] [Article Influence: 9.6] [Reference Citation Analysis]
442 Maiwall R, Kumar S, Chaudhary AK, Maras J, Wani Z, Kumar C, Rastogi A, Bihari C, Vashisht C, Sarin SK. Serum ferritin predicts early mortality in patients with decompensated cirrhosis. J Hepatol 2014;61:43-50. [PMID: 24681346 DOI: 10.1016/j.jhep.2014.03.027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
443 Sharfuddin AA, Weisbord SD, Palevsky PM, Molitoris BA. Acute Kidney Injury. Brenner and Rector's The Kidney. Elsevier; 2012. pp. 1044-99. [DOI: 10.1016/b978-1-4160-6193-9.10030-2] [Cited by in Crossref: 11] [Article Influence: 1.2] [Reference Citation Analysis]
444 Møller S, Bendtsen F, Henriksen JH. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scandinavian Journal of Gastroenterology 2009;40:491-500. [DOI: 10.1080/00365520510012064] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
445 Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, Rendón P, Macías MA, Fernández-Gutiérrez C, Díaz F, Martín-Herrera L. Adhesion molecules as a prognostic marker of liver cirrhosis. Scand J Gastroenterol. 2005;40:217-224. [PMID: 15764154 DOI: 10.1080/00365520510011470] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
446 Heller J, Kristeleit H, Brensing KA, Woitas RP, Spengler U, Sauerbruch T. Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. Scand J Gastroenterol. 1999;34:297-302. [PMID: 10232876 DOI: 10.1080/00365529950173726] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
447 Viasus D, Garcia-Vidal C, Castellote J, Adamuz J, Verdaguer R, Dorca J, Manresa F, Gudiol F, Carratalà J. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine (Baltimore). 2011;90:110-118. [PMID: 21358441 DOI: 10.1097/md.0b013e318210504c] [Cited by in Crossref: 58] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
448 Kamath PS. Is there life in MARS?: Is there life in MARS? Hepatology 2002;36:1017-9. [DOI: 10.1053/jhep.2002.36544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
449 Zheng MH, Wu SJ, Shi KQ, Yan HD, Li H, Zhu GQ, Xie YY, Wu FL, Chen YP. Conditional survival estimate of acute-on-chronic hepatitis B liver failure: a dynamic prediction based on a multicenter cohort. Oncotarget 2015;6:23261-71. [PMID: 26213849 DOI: 10.18632/oncotarget.4666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
450 Kredel M, Brederlau J, Roewer N, Wunder C. [Cholestasis and liver dysfunction in critical care patients]. Anaesthesist 2008;57:1172-82. [PMID: 18989650 DOI: 10.1007/s00101-008-1459-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
451 Sola-Vera J, Miñana J, Ricart E, Planella M, González B, Torras X, Rodríguez J, Such J, Pascual S, Soriano G, Pérez-Mateo M, Guarner C. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-53. [PMID: 12717396 DOI: 10.1053/jhep.2003.50169] [Cited by in Crossref: 138] [Cited by in F6Publishing: 105] [Article Influence: 7.7] [Reference Citation Analysis]
452 Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003;52:1355-1362. [PMID: 12912870 DOI: 10.1136/gut.52.9.1355] [Cited by in Crossref: 120] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
453 Zhao R, Lu J, Shi Y, Zhao H, Xu K, Sheng J. Current management of refractory ascites in patients with cirrhosis. J Int Med Res 2018;46:1138-45. [PMID: 29210304 DOI: 10.1177/0300060517735231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
454 Bernardi M, Blendis L, Burroughs AK, Laffi G, Rodes J, Gentilini P. Hepatorenal syndrome and ascites - questions and answers. Liver Int 1999;19:15-74. [DOI: 10.1111/j.1478-3231.1999.tb00092.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
455 Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, Yang C, Chen PC, Wu CS. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43:673-681. [PMID: 16557538 DOI: 10.1002/hep.21101] [Cited by in Crossref: 192] [Cited by in F6Publishing: 135] [Article Influence: 12.8] [Reference Citation Analysis]
456 Velez JC, Kadian M, Taburyanskaya M, Bohm NM, Delay TA, Karakala N, Rockey DC, Nietert PJ, Goodwin AJ, Whelan TP. Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure. Nephron 2015;131:191-201. [PMID: 26485256 DOI: 10.1159/000441151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
457 Woo GA, O'Brien C. Long-term management of alcoholic liver disease. Clin Liver Dis 2012;16:763-81. [PMID: 23101981 DOI: 10.1016/j.cld.2012.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
458 Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K, Bain VG. The effect of 1 mo of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 2009;29:169-174. [PMID: 18492024 DOI: 10.1111/j.1478-3231.2008.01778.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
459 Gentilini P, Vizzutti F, Gentilini A, La Villa G. Ascites and hepatorenal syndrome. Eur J Gastroenterol Hepatol. 2001;13:313-316. [PMID: 11338056 DOI: 10.1097/00042737-200104000-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
460 Wu KL, Shih CP, Chan JS, Chung CH, Lin HC, Tsao CH, Lin FH, Chien WC, Hsiao PJ. Investigation of the relationship between sensorineural hearing loss and associated comorbidities in patients with chronic kidney disease: A nationwide, population-based cohort study. PLoS One 2020;15:e0238913. [PMID: 32915865 DOI: 10.1371/journal.pone.0238913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
461 Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, Finucci GF, Casiglia E, Sticca A, De Toni R, Pavan L, Gatta A. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998;28:937-943. [PMID: 9755229 DOI: 10.1002/hep.510280407] [Cited by in Crossref: 93] [Cited by in F6Publishing: 76] [Article Influence: 4.0] [Reference Citation Analysis]
462 Lin S, Sun Q, Mao W, Chen Y. Serum Immunoglobulin A (IgA) Level Is a Potential Biomarker Indicating Cirrhosis during Chronic Hepatitis B Infection. Gastroenterol Res Pract 2016;2016:2495073. [PMID: 27123003 DOI: 10.1155/2016/2495073] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
463 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 81] [Article Influence: 10.4] [Reference Citation Analysis]
464 Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133:825-834. [PMID: 17678653 DOI: 10.1053/j.gastro.2007.06.020] [Cited by in Crossref: 355] [Cited by in F6Publishing: 232] [Article Influence: 25.4] [Reference Citation Analysis]
465 Neijenhuis M, Gevers TJG, Atwell TD, Gunneson TJ, Schimek AC, Kievit W, Drenth JPH, Kamath PS. Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites. Am J Gastroenterol 2018;113:567-75. [PMID: 29557942 DOI: 10.1038/ajg.2018.18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
466 Low G, Alexander GJ, Lomas DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract 2015;2015:207012. [PMID: 25649410 DOI: 10.1155/2015/207012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
467 Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther. 2014;5:156-168. [PMID: 25133044 DOI: 10.4292/wjgpt.v5.i3.156] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
468 Aparici CM, Bains SN, Carlson D, Qian J, Liou D, Wojciechowski D, Werner J, Khan S, Kroll C, Sandhu M, Nguyen N, Hawkins R. Recovery of Native Renal Function in Patients with Hepatorenal Syndrome Following Combined Liver and Kidney Transplant with Mercaptoacetyltriglycine-3 Renogram: Developing a Methodology. World J Nucl Med 2016;15:44-9. [PMID: 26912978 DOI: 10.4103/1450-1147.172140] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
469 Dagher, Patch, Marley, Moore, Burroughs. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients: REVIEW: TREATMENT OF HEPATORENAL SYNDROME IN CIRRHOSIS. Alimentary Pharmacology & Therapeutics 2000;14:515-21. [DOI: 10.1046/j.1365-2036.2000.00740.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
470 Kwon HM, Jun IG, Lee J, Moon YJ, Jung KW, Jeong HW, Park YS, Song JG, Hwang GS. Prevalent metabolic derangement and severe thrombocytopenia in ABO-incompatible liver recipients with pre-transplant plasma exchange. Sci Rep 2018;8:6679. [PMID: 29703920 DOI: 10.1038/s41598-018-24887-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
471 Benmassaoud A, Freeman SC, Roccarina D, Plaz Torres MC, Sutton AJ, Cooper NJ, Iogna Prat L, Cowlin M, Milne EJ, Hawkins N, Davidson BR, Pavlov CS, Thorburn D, Tsochatzis E, Gurusamy KS. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2020;1:CD013123. [PMID: 31978257 DOI: 10.1002/14651858.CD013123.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
472 Chung MY, Jun DW, Sung SA. Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis. Korean J Hepatol. 2010;16:301-307. [PMID: 20924213 DOI: 10.3350/kjhep.2010.16.3.301] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
473 Ginès P, Guevara M. Good news for hepatorenal syndrome. Hepatology 2002;36:504-6. [PMID: 12143062 DOI: 10.1053/jhep.2002.35273] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
474 Taki Y, Kanazawa H, Narahara Y, Itokawa N, Kondo C, Fukuda T, Harimto H, Matsushita Y, Kidokoro H, Katakura T, Atsukawa M, Kimura Y, Nakatsuka K, Sakamoto C. Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites. Hepatol Res. 2014;44:871-877. [PMID: 23819607 DOI: 10.1111/hepr.12195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
475 Rifai K, Ernst T, Kretschmer U, Hafer C, Haller H, Manns MP, Fliser D. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 2005;23:298-302. [PMID: 15980619 DOI: 10.1159/000086552] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
476 Inoue Y, Suzuki Y, Ota M, Fujii K, Kawaguchi N, Shimizu T, Asakuma M, Hirokawa F, Hayashi M, Uchiyama K. Comparison of Regeneration of Remnant Liver After Hemihepatectomy with or Without the Middle Hepatic Vein. World J Surg 2018;42:1100-10. [PMID: 28929234 DOI: 10.1007/s00268-017-4225-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
477 Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40:802-810. [PMID: 15382176 DOI: 10.1002/hep.1840400409] [Cited by in Crossref: 369] [Cited by in F6Publishing: 219] [Article Influence: 21.7] [Reference Citation Analysis]
478 Dundar HZ, Yılmazlar T. Management of hepatorenal syndrome. World J Nephrol 2015;4:277-86. [PMID: 25949942 DOI: 10.5527/wjn.v4.i2.277] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
479 Chiu A, Fan ST. MARS in the treatment of liver failure: controversies and evidence. Int J Artif Organs 2006;29:660-7. [PMID: 16874670 DOI: 10.1177/039139880602900703] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
480 Bass NM, Yao FY. The Role of the Interventional Radiologist: Transjugular Procedures. Gastrointestinal Endoscopy Clinics of North America 2001;11:131-61. [DOI: 10.1016/s1052-5157(18)30091-6] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
481 Arroyo V, Fernández J. Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 2011;7:517-26. [DOI: 10.1038/nrneph.2011.96] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
482 Bataller R, Arroyo V, Ginès P. Management of ascites in cirrhosis. J Gastroenterol Hepatol 1997;12:723-33. [PMID: 9430037 DOI: 10.1111/j.1440-1746.1997.tb00360.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
483 Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, Matsuzaki Y, Iwakiri K. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol 2018;33:1256-63. [PMID: 29215154 DOI: 10.1111/jgh.14047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
484 McCormick PA, Donnelly C. Management of hepatorenal syndrome. Pharmacol Ther. 2008;119:1-6. [PMID: 18539334 DOI: 10.1016/j.pharmthera.2008.02.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
485 Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830-835. [PMID: 17939047 DOI: 10.1007/s10620-007-9919-9] [Cited by in Crossref: 126] [Cited by in F6Publishing: 105] [Article Influence: 9.0] [Reference Citation Analysis]
486 Zheng JN, Han YJ, Zou TT, Zhou YJ, Sun DQ, Zhong JH, Braddock M, Zheng MH. Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2017;11:1009-18. [PMID: 28708431 DOI: 10.1080/17474124.2017.1356223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
487 Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia-Tsao G. The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol 2012;10:1169-75. [PMID: 22801062 DOI: 10.1016/j.cgh.2012.06.027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
488 Nilles KM, Levitsky J. Current and Evolving Indications for Simultaneous Liver Kidney Transplantation. Semin Liver Dis 2021;41:308-20. [PMID: 34130337 DOI: 10.1055/s-0041-1729969] [Reference Citation Analysis]
489 Ginès P, Cabrera J, Guevara M, Morillas R, Ruiz del Árbol L, Solà R, Soriano G. Documento de consenso sobre el tratamiento de la ascitis, la hiponatremia dilucional y el síndrome hepatorrenal en la cirrosis hepática. Gastroenterología y Hepatología 2004;27:535-44. [DOI: 10.1016/s0210-5705(03)70522-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
490 Sandhu BS, Sanyal AJ. Hepatorenal syndrome. Curr Treat Options Gastroenterol 2005;8:443-50. [PMID: 16313861 DOI: 10.1007/s11938-005-0030-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
491 Sanyal AJ. Hepatorenal syndrome: Hepatorenal syndrome. Journal of Gastroenterology and Hepatology 2002;17:S248-52. [DOI: 10.1046/j.1440-1746.17.s3.8.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
492 Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P;  Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62:567-574. [PMID: 25644760 DOI: 10.1002/hep.27709] [Cited by in Crossref: 175] [Cited by in F6Publishing: 126] [Article Influence: 29.2] [Reference Citation Analysis]
493 El-Shabrawi MH, Kamal NM. Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations. Paediatr Drugs. 2011;13:371-383. [PMID: 21999650 DOI: 10.2165/11591620-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
494 Reinglas J, Amjadi K, Petrcich B, Momoli F, Shaw-Stiffel T. The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX (©) Catheter. Can J Gastroenterol Hepatol 2016;2016:4680543. [PMID: 27446840 DOI: 10.1155/2016/4680543] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
495 Han MK, Hyzy R. Advances in critical care management of hepatic failure and insufficiency: . Critical Care Medicine 2006;34:S225-31. [DOI: 10.1097/01.ccm.0000231882.85350.71] [Cited by in Crossref: 40] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
496 Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37:233-243. [PMID: 12540770 DOI: 10.1053/jhep.2003.50084] [Cited by in Crossref: 170] [Cited by in F6Publishing: 129] [Article Influence: 9.4] [Reference Citation Analysis]
497 Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087-2107. [PMID: 19475696 DOI: 10.1002/hep.20066] [Cited by in Crossref: 274] [Cited by in F6Publishing: 192] [Article Influence: 22.8] [Reference Citation Analysis]
498 Yan L, Xie F, Lu J, Ni Q, Shi C, Tang C, Yang J. The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2015;15:65. [PMID: 26054761 DOI: 10.1186/s12876-015-0297-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
499 Saló J, Ginès A, Ginès P, Piera C, Jiménez W, Guevara M, Fernández-Esparrach G, Sort P, Bataller R, Arroyo V, Rodés J. Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. J Hepatol 1997;27:645-53. [PMID: 9365040 DOI: 10.1016/s0168-8278(97)80081-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
500 Hunyady B, Jaroszewicz J, Lipták Ľ, Skladaný Ľ, Sperl J, Šváč J. Hepatology topics of special interest from Central Europe (Czech Republic, Hungary, Poland, Slovakia). Clin Exp Hepatol 2016;2:16-20. [PMID: 28856267 DOI: 10.5114/ceh.2016.58852] [Reference Citation Analysis]
501 Uriz J, Ginès P, Ortega R, Jiménez W, Cárdenas A, Calahorra B, Sort P, Fernández J, Bataller R, Arroyo V, Rivera F, Rodés J. Increased plasma levels of neuropeptide Y in hepatorenal syndrome. Journal of Hepatology 2002;36:349-55. [DOI: 10.1016/s0168-8278(01)00286-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
502 Arroyo V, Fernandez J. Pathophysiological basis of albumin use in cirrhosis. Annals of Hepatology 2011;10:S6-S14. [DOI: 10.1016/s1665-2681(19)31600-x] [Cited by in Crossref: 18] [Article Influence: 1.8] [Reference Citation Analysis]
503 Boyer TD. Is transjugular intrahepatic portasystemic shunt a panacea for the complications of portal hypertension? Hepatology 1998;28:590-2. [DOI: 10.1002/hep.510280242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
504 Liangpunsakul S, Agarwal R. Renal failure in cirrhosis: is it time to change the diagnosis and classification? Am J Nephrol. 2013;38:342-344. [PMID: 24107717 DOI: 10.1159/000355570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
505 Cassinello C, Moreno E, Gozalo A, Ortuño B, Cuenca B, Solís-Herruzo JA. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis. Dig Dis Sci 2003;48:179-86. [PMID: 12645807 DOI: 10.1023/a:1021763221337] [Cited by in Crossref: 36] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
506 Scott RA, Austin AS, Kolhe NV, McIntyre CW, Selby NM. Acute kidney injury is independently associated with death in patients with cirrhosis. Frontline Gastroenterol 2013;4:191-7. [PMID: 24660054 DOI: 10.1136/flgastro-2012-100291] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
507 Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options. Semin Intervent Radiol. 2015;32:445-454. [PMID: 26622108 DOI: 10.1055/s-0035-1564794] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
508 Romanelli RG, Laffi G, Vizzutti F, Del Bene R, Marra F, Caini P, Guerra CT, La Villa G, Barletta G. Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis. Dig Liver Dis. 2011;43:314-318. [PMID: 738222 DOI: 10.1016/j.dld.2010.08.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
509 Drolz A, Horvatits T, Roedl K, Rutter K, Brunner R, Zauner C, Schellongowski P, Heinz G, Funk GC, Trauner M, Schneeweiss B, Fuhrmann V. Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. Ann Intensive Care 2018;8:48. [PMID: 29675709 DOI: 10.1186/s13613-018-0391-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
510 Elhassan EA, Schrier RW. Disorders of Extracellular Volume. Comprehensive Clinical Nephrology. Elsevier; 2010. pp. 85-99. [DOI: 10.1016/b978-0-323-05876-6.00007-1] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
511 Ginès P, Terra C, Torre A, Guevara M. [Role of albumin in the treatment of hepatorenal syndrome in cirrhosis]. Gastroenterol Hepatol 2005;28:80-4. [PMID: 15710088 DOI: 10.1157/13070706] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
512 Pinchot JW, Kalva SP, Majdalany BS, Kim CY, Ahmed O, Asrani SK, Cash BD, Eldrup-Jorgensen J, Kendi AT, Scheidt MJ, Sella DM, Dill KE, Hohenwalter EJ; Expert Panels on Interventional Radiology and Vascular Imaging. ACR Appropriateness Criteria® Radiologic Management of Portal Hypertension. J Am Coll Radiol 2021;18:S153-73. [PMID: 33958110 DOI: 10.1016/j.jacr.2021.02.013] [Reference Citation Analysis]
513 Testro AG, Wongseelashote S, Angus PW, Gow PJ. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome. J Gastroenterol Hepatol. 2008;23:1535-1540. [PMID: 17784863 DOI: 10.1111/j.1440-1746.2007.05176.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
514 Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol. 2009;15:67-80. [PMID: 19115470 DOI: 10.3748/wjg.15.67] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
515 Donati G, Piscaglia F, Colì L, Silvagni E, Righini R, Donati G, Pini P, Stefoni S, Bolondi L. Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis: MARS AND HAEMODYNAMIC CHANGES IN CIRRHOSIS. Alimentary Pharmacology & Therapeutics 2007;26:717-26. [DOI: 10.1111/j.1365-2036.2007.03420.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
516 Péron J, Barange K, Otal P, Rousseau H, Payen J, Pascal J, Joffre F, Vinel J. Transjugular Intrahepatic Portosystemic Shunts in the Treatment of Refractory Ascites: Results in 48 Consecutive Patients. Journal of Vascular and Interventional Radiology 2000;11:1211-6. [DOI: 10.1016/s1051-0443(07)61366-9] [Cited by in Crossref: 17] [Article Influence: 0.8] [Reference Citation Analysis]
517 Yan X, Shao R, Wang Y, Mao X, Lei J, Zhang L, Zheng J, Liu A, Zhao H, Gao F, Wang J, Li P, Yao S, Xu M, Xu J, Liu D, Mi Y, Gong X, Ye J, Deng M, Dang T, Ji J, Shao C, Liu C, Gu Y, Wu Y, Wang F, Teng G, Li X, Qi X, Ju S, Qi X. Functional magnetic resonance imaging-based assessment of terlipressin vs. octreotide on renal function in cirrhotic patients with acute variceal bleeding (CHESS1903): study protocol of a multicenter randomized controlled trial. Ann Transl Med 2019;7:586. [PMID: 31807567 DOI: 10.21037/atm.2019.09.141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
518 Seo JH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Ahn SH. Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation. Yonsei Med J 2013;54:145-53. [PMID: 23225811 DOI: 10.3349/ymj.2013.54.1.145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
519 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
520 Angeli P, Rodríguez E, Piano S, Ariza X, Morando F, Solà E, Romano A, García E, Pavesi M, Risso A, Gerbes A, Willars C, Bernardi M, Arroyo V, Ginès P; CANONIC Study Investigators of EASL-CLIF Consortium. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. Gut 2015;64:1616-22. [PMID: 25311034 DOI: 10.1136/gutjnl-2014-307526] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.9] [Reference Citation Analysis]
521 Lasheen AE, Elzeftawy A, Ibrahim S, Attia M, Emam M. Implantation of a skin graft tube to create a saphenoperitoneal shunt for refractory ascites. Surg Today 2007;37:622-5. [PMID: 17593487 DOI: 10.1007/s00595-006-3471-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
522 Attia KA, Ackoundou-N'guessan KC, N'dri-Yoman AT, Mahassadi AK, Messou E, Bathaix YF, Kissi YH. Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. World J Gastroenterol 2008;14:286-91. [PMID: 18186569 DOI: 10.3748/wjg.14.286] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
523 Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, Rodés J, Ginès P. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41:1282-1289. [PMID: 15834937 DOI: 10.1002/hep.20687] [Cited by in Crossref: 241] [Cited by in F6Publishing: 174] [Article Influence: 15.1] [Reference Citation Analysis]
524 Chok KS, Fung JY, Chan SC, Cheung TT, Sharr WW, Chan AC, Fan ST, Lo CM. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl. 2012;18:779-785. [PMID: 22290625 DOI: 10.1002/lt.23401] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
525 Jayakumar S, Chowdhury R, Ye C, Karvellas CJ. Fulminant viral hepatitis. Crit Care Clin. 2013;29:677-697. [PMID: 23830658 DOI: 10.1016/j.ccc.2013.03.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
526 Abraldes J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902-8. [DOI: 10.1053/jhep.2003.50133] [Cited by in Crossref: 362] [Cited by in F6Publishing: 295] [Article Influence: 20.1] [Reference Citation Analysis]
527 Kim JJ, Kim JH, Koo JK, Choi YJ, Ko SY, Choe WH, Kwon SY. The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites. Clin Mol Hepatol 2014;20:47-55. [PMID: 24757658 DOI: 10.3350/cmh.2014.20.1.47] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
528 Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008;48 Suppl 1:S93-S103. [PMID: 18304678 DOI: 10.1016/j.jhep.2008.01.010] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
529 Guevara M, Baccaro ME, Ríos J, Martín-Llahí M, Uriz J, Ruiz del Arbol L, Planas R, Monescillo A, Guarner C, Crespo J, Bañares R, Arroyo V, Ginès P. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int 2010;30:1137-42. [PMID: 20602681 DOI: 10.1111/j.1478-3231.2010.02293.x] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
530 Michl P, Gülberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: Effects in patients with organic or functional renal failure. Scand J Gastroenterol 2000;35:654-8. [PMID: 10912668 DOI: 10.1080/003655200750023642] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
531 Santos J, Planas R, Pardo A, Durández R, Cabré E, Morillas RM, Granada ML, Jiménez JA, Quintero E, Gassull MA. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol. 2003;39:187-192. [PMID: 12873814 DOI: 10.1016/s0168-8278(03)00188-0] [Cited by in Crossref: 104] [Cited by in F6Publishing: 21] [Article Influence: 6.1] [Reference Citation Analysis]
532 Gerth HU, Pohlen M, Thölking G, Pavenstädt H, Brand M, Hüsing-Kabar A, Wilms C, Maschmeier M, Kabar I, Torner J, Pavesi M, Arroyo V, Banares R, Schmidt HHJ. Molecular Adsorbent Recirculating System Can Reduce Short-Term Mortality Among Patients With Acute-on-Chronic Liver Failure-A Retrospective Analysis. Crit Care Med 2017;45:1616-24. [PMID: 28640024 DOI: 10.1097/CCM.0000000000002562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
533 Henriksen JH, Siemssen O, Krintel JJ, Malchow-møller A, Bendtsen F, Ring-larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. Journal of Hepatology 2001;34:53-60. [DOI: 10.1016/s0168-8278(00)00009-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
534 Bari K, Sharma P. Optimizing the Selection of Patients for Simultaneous Liver-Kidney Transplant. Clin Liver Dis 2021;25:89-102. [PMID: 33978585 DOI: 10.1016/j.cld.2020.08.006] [Reference Citation Analysis]
535 Romero-Gómez M, Córdoba J, Jover R, del Olmo JA, Ramírez M, Rey R, de Madaria E, Montoliu C, Nuñez D, Flavia M, Compañy L, Rodrigo JM, Felipo V. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007;45:879-85. [PMID: 17393525 DOI: 10.1002/hep.21586] [Cited by in Crossref: 212] [Cited by in F6Publishing: 176] [Article Influence: 15.1] [Reference Citation Analysis]
536 Saló J, Fernández-esparrach G, Ginès P, Ginès A, Guevara M, Sort P, Jiménez W, Arroyo V, Rivera F, Rodés J. Urinary endothelin-like immunoreactivity in patients with cirrhosis. Journal of Hepatology 1997;27:810-6. [DOI: 10.1016/s0168-8278(97)80317-0] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
537 Bureau C, Garcia-pagan JC, Otal P, Pomier-layrargues G, Chabbert V, Cortez C, Perreault P, Péron JM, G. Abraldes J, Bouchard L, Bilbao JI, Bosch J, Rousseau H, Vinel JP. Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study. Gastroenterology 2004;126:469-75. [DOI: 10.1053/j.gastro.2003.11.016] [Cited by in Crossref: 353] [Cited by in F6Publishing: 263] [Article Influence: 20.8] [Reference Citation Analysis]
538 Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet. 2003;362:1819-1827. [PMID: 14654322 DOI: 10.1016/s0140-6736(03)14903-3] [Cited by in Crossref: 414] [Cited by in F6Publishing: 96] [Article Influence: 24.4] [Reference Citation Analysis]
539 Macdonald S, Jepsen P, Alrubaiy L, Watson H, Vilstrup H, Jalan R. Quality of life measures predict mortality in patients with cirrhosis and severe ascites. Aliment Pharmacol Ther 2019;49:321-30. [PMID: 30585338 DOI: 10.1111/apt.15084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
540 Garcia N, Sanyal AJ. Minimizing ascites: Complication of cirrhosis signals clinical deterioration. Postgraduate Medicine 2015;109:91-103. [DOI: 10.3810/pgm.2001.02.854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
541 Cholongitas E, Calvaruso V, Senzolo M, Patch D, Shaw S, O'beirne J, Burroughs AK. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. Journal of Gastroenterology and Hepatology 2009;24:1639-47. [DOI: 10.1111/j.1440-1746.2009.05908.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
542 Siciliano M, Parlati L, Maldarelli F, Rossi M, Ginanni Corradini S. Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012;3:49-61. [PMID: 22966483 DOI: 10.4292/wjgpt.v3.i4.49] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
543 Wright AS, Rikkers LF. Current management of portal hypertension. J Gastrointest Surg. 2005;9:992-1005. [PMID: 16137597 DOI: 10.1016/j.gassur.2004.09.028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
544 Deep A, Saxena R, Jose B. Acute kidney injury in children with chronic liver disease. Pediatr Nephrol 2019;34:45-59. [PMID: 29497824 DOI: 10.1007/s00467-018-3893-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
545 Saravanan R, Nayar M, Gilmore IT, Smart H, Mcwilliams RG, Rowlands PC, Evans J, Murphy M, Gould D, Taylor S, Sutton R, Lombard MG. Transjugular intrahepatic portosystemic stent shunt: 11 years?? experience at a regional referral centre: . European Journal of Gastroenterology & Hepatology 2005;17:1165-71. [DOI: 10.1097/00042737-200511000-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
546 Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T; North American Study for the Treatment of Refractory Ascites Group. The North American Study for the Treatment of Refractory Ascites. Gastroenterology. 2003;124:634-641. [PMID: 12612902 DOI: 10.1053/gast.2003.50088] [Cited by in Crossref: 307] [Cited by in F6Publishing: 216] [Article Influence: 17.1] [Reference Citation Analysis]
547 De Franchis R, Salerno F. Pathogenesis of ascites and predictors of resistance to therapy. J Gastroenterol Hepatol 2002;17 Suppl 3:S242-7. [PMID: 12472943 DOI: 10.1046/j.1440-1746.17.s3.7.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
548 Yosry A, Soliman ZA, Eletreby R, Hamza I, Ismail A, Elkady MA. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. European Journal of Gastroenterology & Hepatology 2019;31:345-51. [DOI: 10.1097/meg.0000000000001277] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
549 Allegretti AS, Israelsen M, Krag A, Jovani M, Goldin AH, Schulman AR, Winter RW, Gluud LL. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. Cochrane Database Syst Rev 2017;6:CD005162. [PMID: 29943803 DOI: 10.1002/14651858.CD005162.pub4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
550 Mocarzel L, Lanzieri P, Nascimento J, Peixoto C, Ribeiro M, Mesquita E. Hepatorenal syndrome with cirrhotic cardiomyopathy: case report and literature review. Case Reports Hepatol. 2015;2015:573513. [PMID: 25874140 DOI: 10.1155/2015/573513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
551 Chan AC, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, Yong BH, Chiu A, Lam BK. Liver transplantation for acute-on-chronic liver failure. Hepatol Int. 2009;3:571-581. [PMID: 19680733 DOI: 10.1007/s12072-009-9148-8] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 7.3] [Reference Citation Analysis]
552 Biyik M, Ucar R, Solak Y, Gungor G, Polat I, Gaipov A, Cakir OO, Ataseven H, Demir A, Turk S, Polat H. Blood neutrophil-to-lymphocyte ratio independently predicts survival in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2013;25:435-441. [PMID: 23249602 DOI: 10.1097/meg.0b013e32835c2af3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 37] [Article Influence: 9.5] [Reference Citation Analysis]
553 Schepke M, Sauerbruch T. Transjugular portosystemic stent shunt in treatment of liver diseases. World J Gastroenterol 2001;7:170-4. [PMID: 11819756 DOI: 10.3748/wjg.v7.i2.170] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
554 Saab S, Han S, Martin P. LIVER TRANSPLANTATION. Clinics in Liver Disease 2000;4:513-32. [DOI: 10.1016/s1089-3261(05)70124-0] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
555 Sajja KC, Dolmatch BL, Rockey DC. Long-term follow-up of TIPS created with expanded poly-tetrafluoroethylene covered stents. Dig Dis Sci. 2013;58:2100-2106. [PMID: 23381105 DOI: 10.1007/s10620-013-2578-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
556 Cárdenas A, Gines P. Hepatorenal syndrome. Clin Liver Dis 2006;10:371-85, ix-x. [PMID: 16971267 DOI: 10.1016/j.cld.2006.05.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
557 Wong F. The use of TIPS in chronic liver disease. Annals of Hepatology 2006;5:5-15. [DOI: 10.1016/s1665-2681(19)32033-2] [Cited by in Crossref: 29] [Article Influence: 1.9] [Reference Citation Analysis]
558 Wadei HM, Mai ML, Ahsan N, Gonwa TA. Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol. 2006;1:1066-1079. [PMID: 17699328 DOI: 10.2215/cjn.01340406] [Cited by in Crossref: 149] [Cited by in F6Publishing: 44] [Article Influence: 9.9] [Reference Citation Analysis]
559 Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5:127-137. [PMID: 28533910 DOI: 10.1093/gastro/gox009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
560 Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, Arroyo V, Rodés J. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998;27:35-41. [PMID: 9425914 DOI: 10.1002/hep.510270107] [Cited by in Crossref: 235] [Cited by in F6Publishing: 172] [Article Influence: 10.2] [Reference Citation Analysis]
561 Hansrivijit P, Gadhiya KP, Gangireddy M, Goldman JD. Risk Factors, Clinical Characteristics, and Prognosis of Acute Kidney Injury in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. Medicines (Basel) 2021;8:4. [PMID: 33430296 DOI: 10.3390/medicines8010004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
562 Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS;  ADQI Workgroup. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012;16:R23. [PMID: 22322077 DOI: 10.1186/cc11188] [Cited by in Crossref: 99] [Cited by in F6Publishing: 72] [Article Influence: 11.0] [Reference Citation Analysis]
563 Pillebout E. Hepatorenal syndrome. Nephrol Ther. 2014;10:61-68. [PMID: 24388293 DOI: 10.1016/j.nephro.2013.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
564 Bureau C, Métivier S, D’Amico M, Péron JM, Otal P, Pagan JC, Chabbert V, Chagneau-Derrode C, Procopet B, Rousseau H, Bosch J, Vinel JP. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol. 2011;54:901-907. [PMID: 21145798 DOI: 10.1016/j.jhep.2010.08.025] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
565 Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin J, Roudot-thoraval F, Mallat A, Dhumeaux D. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 2002;36:374-80. [DOI: 10.1053/jhep.2002.34343] [Cited by in Crossref: 255] [Cited by in F6Publishing: 174] [Article Influence: 14.2] [Reference Citation Analysis]
566 Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, Jalan R. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134:111-119. [PMID: 18166350 DOI: 10.1053/j.gastro.2007.10.055] [Cited by in Crossref: 127] [Cited by in F6Publishing: 87] [Article Influence: 9.8] [Reference Citation Analysis]
567 Mattos ÂZ, Mattos AA, Ribeiro RA. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol 2016;28:345-51. [PMID: 26649801 DOI: 10.1097/MEG.0000000000000537] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
568 Rivera-Huizar S, Rincón-Sánchez AR, Covarrubias-Pinedo A, Islas-Carbajal MC, Gabriel-Ortíz G, Pedraza-Chaverrí J, Alvarez-Rodríguez A, Meza-García E, Armendáriz-Borunda J. Renal dysfunction as a consequence of acute liver damage by bile duct ligation in cirrhotic rats. Exp Toxicol Pathol. 2006;58:185-195. [PMID: 16829063 DOI: 10.1016/j.etp.2006.05.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
569 Lodato F, Berzigotti A, Lisotti A, Azzaroli F, Mosconi C, Giampalma E, Renzulli M, Cappelli A, Buonfiglioli F, Calvanese C, Zoli M, Golfieri R, Mazzella G. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. Scandinavian Journal of Gastroenterology 2012;47:1494-500. [DOI: 10.3109/00365521.2012.703239] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
570 Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-tsao G. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of Hepatology 2015;62:968-74. [DOI: 10.1016/j.jhep.2014.12.029] [Cited by in Crossref: 333] [Cited by in F6Publishing: 249] [Article Influence: 55.5] [Reference Citation Analysis]
571 Rendón Unceta P, Alberto Macías Rodríguez M, Guillén Mariscal P, Tejada Cabrera M, Carmen Martínez Sierra M, Martín Herrera L. Ecografía Doppler renal y su relación con la función renal en pacientes con cirrosis hepática. Medicina Clínica 2001;116:561-4. [DOI: 10.1016/s0025-7753(01)71906-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
572 Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863-71. [PMID: 18027874 DOI: 10.1002/hep.21901] [Cited by in Crossref: 103] [Cited by in F6Publishing: 86] [Article Influence: 7.9] [Reference Citation Analysis]
573 Mahmoud WA, Abdelkader NA, Mansor A. Could serum nitrate and nitrite levels possibly predict hepatorenal syndrome in hepatitis C virus-related liver cirrhosis? Indian J Gastroenterol 2014;33:274-80. [PMID: 24287875 DOI: 10.1007/s12664-013-0427-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
574 Khatua CR, Sahu SK, Barik RK, Pradhan S, Panigrahi S, Mishra D, Singh SP. Validation of International Club of Ascites subclassification of stage 1 acute kidney injury in chronic liver disease. JGH Open 2019;3:290-4. [PMID: 31406921 DOI: 10.1002/jgh3.12152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
575 Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002;14:153-158. [PMID: 11981339 DOI: 10.1097/00042737-200202000-00009] [Cited by in Crossref: 90] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
576 Bozanich NK, Kwo PY. Renal Insufficiency in the Patient with Chronic Liver Disease. Clinics in Liver Disease 2015;19:45-56. [DOI: 10.1016/j.cld.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
577 Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016;63:983-992. [PMID: 26659927 DOI: 10.1002/hep.28396] [Cited by in Crossref: 126] [Cited by in F6Publishing: 78] [Article Influence: 25.2] [Reference Citation Analysis]
578 Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK. Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. J Hepatol. 2012;56:348-354. [PMID: 21749847 DOI: 10.1016/j.jhep.2011.04.027] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
579 Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, Tamez H, Chung RT, Karumanchi SA, Thadhani RI. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol. 2015;2015:108139. [PMID: 26266048 DOI: 10.1155/2015/108139] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
580 Saner FH, Canbay A, Gerken G, Broelsch CE. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Review of Gastroenterology & Hepatology 2014;1:207-17. [DOI: 10.1586/17474124.1.2.207] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
581 Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064-77. [PMID: 19003880 DOI: 10.1002/hep.22605] [Cited by in Crossref: 385] [Cited by in F6Publishing: 296] [Article Influence: 32.1] [Reference Citation Analysis]
582 El-Sheikh RM, Mansy SS, Nessim IG, Hosni HN, El Hindawi A, Hassanein MH, AbdelFattah AS. Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection. APMIS. 2019;127:93-105. [PMID: 30698308 DOI: 10.1111/apm.12917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
583 Leithead JA, Armstrong MJ, Corbett C, Andrew M, Kothari C, Gunson BK, Muiesan P, Ferguson JW. Hepatic ischemia reperfusion injury is associated with acute kidney injury following donation after brain death liver transplantation. Transpl Int. 2013;26:1116-1125. [PMID: 24033747 DOI: 10.1111/tri.12175] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
584 Planinsic RM, Lebowitz JJ. Renal failure in end-stage liver disease and liver transplantation. Int Anesthesiol Clin. 2006;44:35-49. [PMID: 16832205 DOI: 10.1097/01.aia.0000210807.24298.f7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
585 Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci. 2006;51:1637-1643. [PMID: 16927139 DOI: 10.1007/s10620-006-9099-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
586 Best LM, Freeman SC, Sutton AJ, Cooper NJ, Tng EL, Csenar M, Hawkins N, Pavlov CS, Davidson BR, Thorburn D, Cowlin M, Milne EJ, Tsochatzis E, Gurusamy KS. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2019;9:CD013103. [PMID: 31513287 DOI: 10.1002/14651858.cd013103.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
587 Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol. 2016;65:809-824. [PMID: 27238754 DOI: 10.1016/j.jhep.2016.05.025] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 14.2] [Reference Citation Analysis]
588 Kim TS, Joh JW, Moon H, Lee S, Song SH, Shin M, Kim JM, Kwon CH, Kim SJ, Lee SK. The different etiology of fulminant hepatic failure (FHF) in Korea and prognostic factors in patients undergoing liver transplantation for FHF. Clin Transplant 2013;27:297-302. [PMID: 23278635 DOI: 10.1111/ctr.12055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
589 Rai N, Singh B, Singh A, Vijayvergiya R, Sharma N, Bhalla A, Singh V. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. Liver Int 2017;37:406-14. [DOI: 10.1111/liv.13250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
590 Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104:1802-1829. [PMID: 19455106 DOI: 10.1038/ajg.2009.191] [Cited by in Crossref: 168] [Cited by in F6Publishing: 141] [Article Influence: 14.0] [Reference Citation Analysis]
591 de Carvalho JR, Villela-Nogueira CA, Luiz RR, Guzzo PL, da Silva Rosa JM, Rocha E, Moraes Coelho HS, de Mello Perez R. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J Clin Gastroenterol. 2012;46:e21-e26. [PMID: 21934526 DOI: 10.1097/mcg.0b013e31822e8e12] [Cited by in Crossref: 68] [Cited by in F6Publishing: 24] [Article Influence: 7.6] [Reference Citation Analysis]
592 Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P; Terlipressin Study Group. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-8. [PMID: 18471513 DOI: 10.1053/j.gastro.2008.02.014] [Cited by in Crossref: 405] [Cited by in F6Publishing: 300] [Article Influence: 31.2] [Reference Citation Analysis]
593 Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998;27:264-72. [PMID: 9425946 DOI: 10.1002/hep.510270139] [Cited by in Crossref: 170] [Cited by in F6Publishing: 114] [Article Influence: 7.4] [Reference Citation Analysis]
594 Jalan R, Hayes PC. Hepatic encephalopathy and ascites. The Lancet 1997;350:1309-15. [DOI: 10.1016/s0140-6736(97)07503-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
595 Williams EJ, Iredale JP. Liver cirrhosis. Postgrad Med J. 1998;74:193-202. [PMID: 9683971 DOI: 10.1136/pgmj.74.870.193] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
596 Ha JM, Sohn W, Cho JY, Pyo JH, Choi K, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Paik YH. Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. Clin Mol Hepatol 2015;21:232-41. [PMID: 26523268 DOI: 10.3350/cmh.2015.21.3.232] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
597 Huelin P, Solà E, Elia C, Solé C, Risso A, Moreira R, Carol M, Fabrellas N, Bassegoda O, Juanola A, de Prada G, Albertos S, Piano S, Graupera I, Ariza X, Napoleone L, Pose E, Filella X, Morales-Ruiz M, Rios J, Fernández J, Jiménez W, Poch E, Torres F, Ginès P. Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology 2019;70:319-33. [PMID: 30810244 DOI: 10.1002/hep.30592] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
598 Lavayssière L, Kallab S, Cardeau-Desangles I, Nogier MB, Cointault O, Barange K, Muscari F, Rostaing L, Kamar N. Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure. J Gastroenterol Hepatol. 2013;28:1019-1024. [PMID: 23425070 DOI: 10.1111/jgh.12159] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
599 Tuttolomondo A, Pinto A, Parrinello G, Licata G. Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites. Semin Nephrol 2011;31:513-22. [PMID: 22099508 DOI: 10.1016/j.semnephrol.2011.09.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
600 Luedemann C, Plota J, Nattermann J, Strassburg CP, Lutz P, Goeser F. Renal replacement therapy as bridging-to-recovery in refractory hepatorenal syndrome. Z Gastroenterol 2021;59:331-5. [PMID: 33634437 DOI: 10.1055/a-1369-9859] [Reference Citation Analysis]
601 Macken L, Mason L, Evans C, Gage H, Jordan J, Austin M, Parnell N, Cooper M, Steer S, Boles J, Bremner S, Lambert D, Crook D, Earl G, Timeyin J, Verma S. Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis: study protocol for a feasibility randomised controlled trial. Trials 2018;19:401. [PMID: 30053891 DOI: 10.1186/s13063-018-2779-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
602 Risør LM, Bendtsen F, Møller S. Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction. Hepatol Int 2015;9:17-27. [DOI: 10.1007/s12072-014-9581-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
603 Owen AR, Stanley AJ, Vijayananthan A, Moss JG. The transjugular intrahepatic portosystemic shunt (TIPS). Clin Radiol. 2009;64:664-674. [PMID: 19520210 DOI: 10.1016/j.crad.2008.09.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
604 Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797-805. [PMID: 17326206 DOI: 10.1002/hep.21563] [Cited by in Crossref: 914] [Cited by in F6Publishing: 760] [Article Influence: 65.3] [Reference Citation Analysis]
605 Jang BK, Lee SH, Chung WJ, Park KS, Cho KB, Hwang JS, Kim YH, Choi JS, Kwon JH. Incidence and risk factors of acute renal failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J Hepatol 2008;14:168. [DOI: 10.3350/kjhep.2008.14.2.168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
606 Kade G, Lubas A, Spaleniak S, Wojtecka A, Leśniak K, Literacki S, Niemczyk S, Dyrla P. Application of the Molecular Adsorbent Recirculating System in Type 1 Hepatorenal Syndrome in the Course of Alcohol-Related Acute on Chronic Liver Failure. Med Sci Monit 2020;26:e923805. [PMID: 32602472 DOI: 10.12659/MSM.923805] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
607 Inoue Y, Fujii K, Tashiro K, Ishii M, Masubuchi S, Yamamoto M, Shimizu T, Asakuma M, Hirokawa F, Hayashi M, Narumi Y, Uchiyama K. Preoperative Chemotherapy May Not Influence the Remnant Liver Regenerations and Outcomes After Hepatectomy for Colorectal Liver Metastasis. World J Surg. 2018;42:3316-3330. [PMID: 29549511 DOI: 10.1007/s00268-018-4590-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
608 Pfortmueller CA, Wiemann C, Funk GC, Leichtle AB, Fiedler GM, Exadaktylos AK, Lindner G. Hypoglycemia is associated with increased mortality in patients with acute decompensated liver cirrhosis. J Crit Care. 2014;29:316.e7-316.12. [PMID: 24332992 DOI: 10.1016/j.jcrc.2013.11.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
609 Alferink LJM, Oey RC, Hansen BE, Polak WG, van Buuren HR, de Man RA, Schurink CAM, Metselaar HJ. The impact of infections on delisting patients from the liver transplantation waiting list. Transpl Int 2017;30:807-16. [PMID: 28403563 DOI: 10.1111/tri.12965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
610 Bhanji RA, Carey EJ, Watt KD. Review article: maximising quality of life while aspiring for quantity of life in end-stage liver disease. Aliment Pharmacol Ther. 2017;46:16-25. [PMID: 28464346 DOI: 10.1111/apt.14078] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
611 Ruiz R, Barri YM, Jennings LW, Chinnakotla S, Goldstein RM, Levy MF, McKenna GJ, Randall HB, Sanchez EQ, Klintmalm GB. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl. 2007;13:838-843. [PMID: 17539003 DOI: 10.1002/lt.21149] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
612 Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Christos P, Paraskevi K, Konstantinos P, Katsaraki A, Tsianos EV. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Dig Dis Sci. 2005;50:1771-1777. [PMID: 16187171 DOI: 10.1007/s10620-005-2935-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
613 Poordad FF, Sigal SH, Brown RS. Pathophysiologic basis for the medical management of portal hypertension. Expert Opin Pharmacother. 2009;10:453-467. [PMID: 19191681 DOI: 10.1517/14656560802707853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
614 Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol. 2013;11:1550-1558. [PMID: 23583467 DOI: 10.1016/j.cgh.2013.03.018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
615 Zaza S, Bonny O, Liaudet L. Le syndrome hépatorénal chez le patient cirrhotique. Néphrologie & Thérapeutique 2005;1:174-82. [DOI: 10.1016/j.nephro.2005.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
616 Benjamin J, Singla V, Arora I, Sood S, Joshi YK. Intestinal permeability and complications in liver cirrhosis: A prospective cohort study. Hepatol Res. 2013;43:200-207. [PMID: 22726344 DOI: 10.1111/j.1872-034x.2012.01054.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
617 Appenrodt B, Lammert F. Renal Failure in Patients with Liver Cirrhosis: Novel Classifications, Biomarkers, Treatment. Visc Med 2018;34:246-52. [PMID: 30345281 DOI: 10.1159/000492587] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
618 Walker NM, Stuart KA, Ryan RJ, Desai S, Saab S, Nicol JA, Fletcher LM, Crawford DH. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology. 2010;51:1683-1691. [PMID: 20225256 DOI: 10.1002/hep.23537] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
619 Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11:336-343. [PMID: 15719386 DOI: 10.1002/lt.20329] [Cited by in Crossref: 284] [Cited by in F6Publishing: 240] [Article Influence: 17.8] [Reference Citation Analysis]
620 Angeli P, Tonon M, Pilutti C, Morando F, Piano S. Sepsis-induced acute kidney injury in patients with cirrhosis. Hepatol Int. 2016;10:115-123. [PMID: 26141259 DOI: 10.1007/s12072-015-9641-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
621 Zhang CC, Hoffelt DAA, Merle U. Urinary cell cycle arrest biomarker [TIMP-2]·[IGFBP7] in patients with hepatorenal syndrome. Biomarkers 2019;24:692-9. [DOI: 10.1080/1354750x.2019.1652347] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
622 Karwa R, Woodis CB. Midodrine and Octreotide in Treatment of Cirrhosis-Related Hemodynamic Complications. Ann Pharmacother 2009;43:692-9. [DOI: 10.1345/aph.1l373] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
623 Turk T, Al Saadi T, Sawaf B, Alkhatib M, Zakaria MI, Daaboul B. Progressive liver failure post acute hepatitis A, over a three-month period, resulting in hepatorenal syndrome and death. Gastroenterol Rep (Oxf) 2017;5:161-4. [PMID: 27247182 DOI: 10.1093/gastro/gow009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
624 Carreiro G, Moreira ADL, Murad FF, Azevedo F, Coelho HSM. TIPS - anastomose portossistêmica intra-hepática transjugular. Revisão. Arq Gastroenterol 2001;38:69-80. [DOI: 10.1590/s0004-28032001000100013] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
625 Urrunaga NH, Mindikoglu AL, Rockey DC. Renal dysfunction in cirrhosis. Curr Opin Gastroenterol 2015;31:215-23. [PMID: 25763790 DOI: 10.1097/MOG.0000000000000168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
626 Goyal N, Jain N, Rachapalli V, Cochlin DL, Robinson M. Non-invasive evaluation of liver cirrhosis using ultrasound. Clin Radiol. 2009;64:1056-1066. [PMID: 19822238 DOI: 10.1016/j.crad.2009.05.010] [Cited by in Crossref: 75] [Cited by in F6Publishing: 50] [Article Influence: 6.3] [Reference Citation Analysis]
627 Clària J, Kent JD, López-Parra M, Escolar G, Ruiz-Del-Arbol L, Ginès P, Jiménez W, Vucelic B, Arroyo V. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41:579-587. [PMID: 15723448 DOI: 10.1002/hep.20595] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
628 Kramer L, Bauer E, Gendo A, Madl C, Gangl A. Influence of Hydroxy Ethyl Starch Infusion on Serum Bilirubin Levels in Cirrhotic Patients Treated with Artificial Liver Support. Int J Artif Organs 2002;25:918-22. [DOI: 10.1177/039139880202501004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
629 Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002;36:949-58. [PMID: 12297843 DOI: 10.1053/jhep.2002.36130] [Cited by in Crossref: 284] [Cited by in F6Publishing: 220] [Article Influence: 14.9] [Reference Citation Analysis]
630 Hamdy H, ElBaz AA, Hassan A, Hassanin O. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study. J Clin Gastroenterol 2014;48:184-8. [PMID: 23842215 DOI: 10.1097/MCG.0b013e31829ae376] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 2.9] [Reference Citation Analysis]
631 Saner FH, Frühauf NR, Schäfers RF, Lang H, Malagó M, Broelsch CE. Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. Eur J Gastroenterol Hepatol 2003;15:925-7. [PMID: 12867805 DOI: 10.1097/00042737-200308000-00015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
632 Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416-428. [PMID: 19669317 DOI: 10.1007/s12072-008-9100-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
633 Teperman L. Living donation for the very ill patient with type I hepatorenal syndrome: are we ready? Liver Transpl 2012;18:753-4. [PMID: 22511366 DOI: 10.1002/lt.23455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
634 Low G, Owen NE, Joubert I, Patterson AJ, Graves MJ, Alexander GJ, Lomas DJ. Magnetic resonance elastography in the detection of hepatorenal syndrome in patients with cirrhosis and ascites. Eur Radiol. 2015;25:2851-2858. [PMID: 25903705 DOI: 10.1007/s00330-015-3723-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
635 Francoz C, Belghiti J, Castaing D, Chazouillères O, Duclos-vallée J, Duvoux C, Lerut J, Le Treut Y, Moreau R, Mandot A, Pageaux G, Samuel D, Thabut D, Valla D, Durand F. Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score-based liver allocation system: Meld Exceptions in the French System. Liver Transpl 2011;17:1137-51. [DOI: 10.1002/lt.22363] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
636 Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol 2020;18:457-467.e21. [PMID: 31306800 DOI: 10.1016/j.cgh.2019.07.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
637 Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant. 2006;21:478-482. [PMID: 16249201 DOI: 10.1093/ndt/gfi212] [Cited by in Crossref: 101] [Cited by in F6Publishing: 80] [Article Influence: 6.3] [Reference Citation Analysis]
638 Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver. 2002;22 Suppl 2:5-13. [PMID: 12220296 DOI: 10.1034/j.1600-0676.2002.00001.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 121] [Article Influence: 7.2] [Reference Citation Analysis]
639 Reynolds TB. ASCITES. Clinics in Liver Disease 2000;4:151-68. [DOI: 10.1016/s1089-3261(05)70101-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
640 Baccaro ME, Guevara M, Rodés J. Ascites. The Foundation Years 2007;3:57-60. [DOI: 10.1016/j.mpfou.2007.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
641 Hassoun Z, Pomier-Layrargues G. The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension. Eur J Gastroenterol Hepatol. 2004;16:1-4. [PMID: 15095845 DOI: 10.1097/00042737-200401000-00001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
642 Syed MI, Karsan H, Ferral H, Shaikh A, Waheed U, Akhter T, Gabbard A, Morar K, Tyrrell R. Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension. World J Hepatol. 2012;4:35-42. [PMID: 22400084 DOI: 10.4254/wjh.v4.i2.35] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
643 Ginès P, Arroyo V. Hepatorenal Syndrome. JASN 1999;10:1833-9. [DOI: 10.1681/asn.v1081833] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
644 Wang Y, Liu LP, Bai WY, Wen SB, Dan HJ, Luan YY, Zeng MX, Hu B. Renal haemodynamics in patients with liver cirrhosis assessed by colour ultrasonography. J Int Med Res 2011;39:249-55. [PMID: 21672328 DOI: 10.1177/147323001103900127] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
645 Bolarín JM, Pérez-Cárceles MD, Hernández Del Rincón JP, Luna A, Minguela A, Muro M, Legaz I. Causes of Death and Survival in Alcoholic Cirrhosis Patients Undergoing Liver Transplantation: Influence of the Patient's Clinical Variables and Transplant Outcome Complications. Diagnostics (Basel) 2021;11:968. [PMID: 34072173 DOI: 10.3390/diagnostics11060968] [Reference Citation Analysis]
646 Sundaram V, Manne V, Al-Osaimi AM. Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol. 2014;20:279-287. [PMID: 25253362 DOI: 10.4103/1319-3767.141686] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
647 Qasim A, O’Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther. 2002;16 Suppl 1:24-30. [PMID: 11849124 DOI: 10.1046/j.1365-2036.16.s5.4.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
648 Tonon M, Piano S, Gambino CG, Romano A, Pilutti C, Incicco S, Brocca A, Sticca A, Bolognesi M, Angeli P. Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2020;. [PMID: 32272250 DOI: 10.1016/j.cgh.2020.03.065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
649 Wang L, Long Y, Li KX, Xu GS. Pharmacological treatment of hepatorenal syndrome: a network meta-analysis.Gastroenterol Rep (Oxf). 2020;8:111-118. [PMID: 32280470 DOI: 10.1093/gastro/goz043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
650 Angeli P, Morando F. Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepat Med 2010;2:87-98. [PMID: 24367209 DOI: 10.2147/hmer.s6918] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
651 Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017;45:1390-1402. [PMID: 28370090 DOI: 10.1111/apt.14052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
652 Chan MM, Chan MM, Mengshol JA, Fish DN, Chan ED. Octreotide. Chest 2013;144:1937-45. [DOI: 10.1378/chest.13-0382] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
653 Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004;40:140-146. [PMID: 14672625 DOI: 10.1016/j.jhep.2003.09.019] [Cited by in Crossref: 164] [Cited by in F6Publishing: 120] [Article Influence: 9.6] [Reference Citation Analysis]
654 Pomier-Layrargues G, Bouchard L, Lafortune M, Bissonnette J, Guérette D, Perreault P. The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status. Int J Hepatol. 2012;2012:167868. [DOI: 10.1155/2012/167868] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
655 Saif MW, Siddiqui IA, Sohail MA. Management of ascites due to gastrointestinal malignancy. Ann Saudi Med. 2009;29:369-377. [PMID: 19700895 DOI: 10.4103/0256-4947.55167] [Cited by in Crossref: 52] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
656 Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia-Tsao G, Jimenez W, Planas R, Arroyo V. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258-266. [PMID: 12830009 DOI: 10.1053/jhep.2003.50315] [Cited by in Crossref: 533] [Cited by in F6Publishing: 401] [Article Influence: 29.6] [Reference Citation Analysis]
657 Prakoso E, Jones C, Koorey DJ, Strasser SI, Bowen D, McCaughan GW, Shackel NA. Terlipressin therapy for moderate-to-severe hyponatraemia in patients with liver failure. Intern Med J 2013;43:240-6. [PMID: 23176166 DOI: 10.1111/imj.12032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
658 Sansoè G, Aragno M, Mastrocola R, Parola M. Dose-dependency of clonidine's effects in ascitic cirrhotic rats: comparison with α1-adrenergic agonist midodrine. Liver Int 2016;36:205-11. [PMID: 26121993 DOI: 10.1111/liv.12905] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
659 Rössle M, Siegerstetter V, Huber M, Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 1998;18:73-89. [DOI: 10.1111/j.1600-0676.1998.tb00132.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 119] [Article Influence: 11.3] [Reference Citation Analysis]
660 Borentain P, Soussan J, Resseguier N, Botta-Fridlund D, Dufour JC, Gérolami R, Vidal V. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement. Diagn Interv Imaging 2016;97:643-50. [PMID: 26947721 DOI: 10.1016/j.diii.2016.02.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
661 Bucsics T, Schwabl P, Mandorfer M, Bota S, Sieghart W, Ferlitsch A, Trauner M, Reiberger T, Peck-Radosavljevic M. The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver Int 2016;36:1649-56. [PMID: 27169985 DOI: 10.1111/liv.13160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
662 Charlton MR, Wall WJ, Ojo AO, Ginès P, Textor S, Shihab FS, Marotta P, Cantarovich M, Eason JD, Wiesner RH. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl. 2009;15:S1-34. [PMID: 19877213 DOI: 10.1002/lt.21877] [Cited by in Crossref: 105] [Cited by in F6Publishing: 77] [Article Influence: 9.5] [Reference Citation Analysis]
663 Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia-Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010;30:937-947. [PMID: 20492521 DOI: 10.1111/j.1478-3231.2010.02272.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 80] [Article Influence: 10.1] [Reference Citation Analysis]
664 Martin PY, Ohara M, Gines P, Xu DL, St John J, Niederberger M, Schrier RW. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest. 1998;101:235-242. [PMID: 9421486 DOI: 10.1172/jci626] [Cited by in Crossref: 97] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
665 Silvestre OM, Bacal F, Ramos DDS, Andrade JL, Furtado M, Pugliese V, Belleti E, Andraus W, Carrilho FJ, D’albuquerque LAC, Farias AQ. Impact of the severity of end-stage liver disease in cardiac structure and function. Annals of Hepatology 2013;12:85-91. [DOI: 10.1016/s1665-2681(19)31389-4] [Cited by in Crossref: 18] [Article Influence: 2.3] [Reference Citation Analysis]
666 Zhang J, Liu J, Wu Y, Romeiro FG, Levi Sandri GB, Zhou X, Li M, Qi X. Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding. Ann Transl Med 2020;8:340. [PMID: 32355784 DOI: 10.21037/atm.2020.02.135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
667 Vidot H, Bowen DG, Carey S, McCaughan GW, Allman-Farinelli M, Shackel NA. Aggressive nutrition intervention reduces ascites and frequency of paracentesis in malnourished patients with cirrhosis and ascites. JGH Open 2017;1:92-7. [PMID: 30483543 DOI: 10.1002/jgh3.12016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
668 Fiacco F, Melandro F, Umbro I, Zavatto A, Cappoli A, Poli E, Ginanni Corradini S, Merli M, Tinti F, Nofroni I, Berloco PB, Rossi M, Mitterhofer AP. Fluctuations of Estimated Glomerular Filtration Rate Outside Kidney Disease Improving Global Outcomes Diagnostic Criteria for Acute Kidney Injury in End-Stage Liver Disease Outpatients and Outcome Postliver Transplantation. Transplant Direct 2018;4:e222. [PMID: 29399624 DOI: 10.1097/TXD.0000000000000733] [Reference Citation Analysis]
669 Regner KR, Singbartl K. Kidney Injury in Liver Disease. Crit Care Clin. 2016;32:343-355. [PMID: 27339675 DOI: 10.1016/j.ccc.2016.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
670 Péron J, Bureau C, Vinel J. Place du TIPS dans le traitement de l’ascite réfractaire. Gastroentérologie Clinique et Biologique 2007;31:341-6. [DOI: 10.1016/s0399-8320(07)89387-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
671 Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol. 2002;37:767-772. [PMID: 738222 DOI: 10.1016/S0168-8278(02)00295-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
672 Leithead JA, Rajoriya N, Gunson BK, Ferguson JW. Neutrophil-to-lymphocyte ratio predicts mortality in patients listed for liver transplantation. Liver Int. 2015;35:502-509. [PMID: 25234369 DOI: 10.1111/liv.12688] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
673 Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol. 2009;51:475-482. [PMID: 19560225 DOI: 10.1016/j.jhep.2009.04.017] [Cited by in Crossref: 156] [Cited by in F6Publishing: 141] [Article Influence: 13.0] [Reference Citation Analysis]
674 Kiser TH, Maclaren R, Fish DN. Treatment of hepatorenal syndrome. Pharmacotherapy. 2009;29:1196-1211. [PMID: 19792993 DOI: 10.1592/phco.29.10.1196] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
675 Inoue Y, Yokohama K, Ohama H, Tsuchimoto Y, Terazawa T, Asai A, Fukunishi S, Okuda J, Higuchi K, Uchiyama K. Efficacy and safety of laparoscopic hepatectomy for hepatocellular carcinoma comorbid with cirrhosis. Prz Gastroenterol 2020;15:225-33. [PMID: 33005268 DOI: 10.5114/pg.2020.99039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
676 Gupta K, Rani P, Rohatgi A, Verma M, Handa S, Dalal K, Jain A. Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. Clin Exp Gastroenterol. 2018;11:317-324. [PMID: 30271187 DOI: 10.2147/ceg.s153858] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [R